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Abstract 
 
Polymorphous low grade adenocarcinoma (PLGA) is the second most common 
malignant salivary gland tumour of the minor salivary glands. Human tissue kallikreins 
(KLKs) are a family of highly conserved serine proteases expressed by various tissues 
throughout the body. KLKs have become powerful tumour markers for the diagnosis of the 
cancer patient (e.g. PSA (KLK3)). The literature demonstrates a link between KLKs and 
salivary gland neoplasms. The purpose of this study is to determine levels of KLK mRNA 
in tissue samples of formalin fixed paraffin embedded polymorphous low grade 
adenocarcinoma (PLGA). Secondly, we wish to determine if KLK expression is limited to 
tumour cells alone.  
Nineteen cases of PLGA were reviewed (1987-2013). A diagnosis of PLGA was 
confirmed, demographic data was collected, and formalin fixed paraffin-embedded PLGA 
and normal salivary gland tissue samples were obtained. RNA isolation was achieved, 
followed by conversion to complementary DNA via reverse transcription. Synthesized 
DNA primers were added to target kallikrein DNA and through PCR, the quantitative level 
of expression of KLKs 1-15 was recorded. Samples exhibiting high and low KLK 
expression were selected for immunohistochemistry staining, using a standard protocol. 
Results from PCR data reveals statistically significant increase in the mean KLK 
mRNA expression for KLK1, KLK4, KLK10, KLK12 and KLK15 in PLGA tissue 
samples, as compared with normal salivary gland tissue (Mann Whitney U test, p<0.05). 
Immunohistochemistry results demonstrate tumour specific staining. Notably, all samples 
demonstrating relatively higher KLK mRNA expression showed equivalent or increased 
staining grade scores relative to the low KLK mRNA expression samples, with respect to 
a specific KLK. 
In tissue samples of polymorphous low grade adenocarcinoma there is an increase 
of KLK1, KLK4, KLK10, KLK12 and KLK15 mRNA relative to normal salivary gland 
tissue. Furthermore, the tumour cells stain positively and specifically for kallikreins. 
 
Keywords: Salivary gland neoplasm, polymorphous low-grade adenocarcinoma, human 
tissue kallikreins, RT-PCR, immunohistochemistry, biomarkers 
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Chapter 1 
 
1.0 Introduction 
 
1.1 Salivary Gland Neoplasms 
Salivary gland tumours comprise 2-6.5% of all head and neck malignancies and have a 
global incidence of approximately 1-6.5 cases per 100,000 persons annually[1, 2]. These tumours 
are most commonly found in the parotid gland, but may also occur in the other major salivary 
gland tissue, the submandibular and sublingual glands, as well as the minor salivary glands[2, 3]. 
The minor salivary glands are widely distributed along the upper aerodigestive tract, including the 
lips, gingiva, buccal mucosa, palate, tongue, oropharynx, paranasal sinuses, and the 
parapharyngeal space[4].  
Although the parotid comprises 64-80% of all salivary gland neoplasia cases, only about 
15-32% of these tumours are malignant[2, 5]. The most common benign salivary gland tumour of 
the parotid gland is pleomorphic adenoma (PA), whereas the most common malignancy is 
mucoepidermoid carcinoma (MEC)[1, 2, 5]. Submandibular glands account for about 8-11% of 
salivary gland tumours; however, the rate of malignancy is substantially higher, ranging from 37-
45%[2]. Still, PA remains the most common benign entity, and adenoid cystic carcinoma (ACC) 
is the most common malignancy, found in the submandibular glands[2]. Tumours in the sublingual 
gland are rare, occurring <1%, but the gross majority are malignancies[2]. Minor salivary glands 
comprise 9-23% of salivary gland tumours[2]. They are more common to be malignant, with MEC 
being the most common malignant tumour of the minor salivary glands[2, 5]. 
 
1.1.1 Polymorphous Low-Grade Adenocarcinoma 
Polymorphous low-grade adenocarcinoma (PLGA) was first described in 1983 by 
Freedman and Lumerman, and Batsakis et al. as “lobular carcinoma” and “terminal duct 
carcinoma” for its similarities to lobular carcinoma of the breast[6-9]. In 1984, the term 
“polymorphous low-grade adenocarcinoma” was suggested by Evans and Batsakis, and, 
subsequently, it was recognized as its own entity by the World Health Organization (WHO) in 
1990[9-12]. Previous to this, it was considered under the umbrella of pleomorphic adenoma, 
adenocarcinoma NOS, or ACC[2, 13]. By definition, PLGA is a “malignant epithelial tumour 
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characterized by cellular uniformity, morphologic diversity, an infiltrative growth pattern, and low 
metastatic potential”[3]. PLGA is a diagnostic challenge for pathologist, overlapping in histologic 
characteristics with other salivary gland neoplasms[14].  
 
1.1.1.1 Epidemiology, demographics 
PLGA is the second most common malignant salivary gland tumour of the minor glands 
and the third most common salivary gland tumour found in the oral cavity[14, 15]. It comprises 7-
11% of all tumours in the minor salivary glands, and 19-26% of all malignancies of the minor 
salivary glands[9]. PLGA is not limited to minor salivary glands, but may occur in major salivary 
glands or from an existing pleomorphic adenoma; however, in both instances this is rare[8, 9, 11]. 
In a 2015 retrospective study, the incidence of PLGA was noted to be 0.051 per 100000 persons 
annually[11].  In their 2013 epidemiologic study, de Araujo et al. noted a significant increase in 
the fraction of PLGA cases reported in the literature since 2007, but did suggest this was secondary 
to improved diagnostic accuracy by pathologists[16]. PLGA is most commonly found in the 
Caucasian population; however, some publications have reported higher incidences amongst Asian 
and African populations [11, 16, 17]. Two retrospective studies out of Northeast and Eastern China 
documented a lower incidence of PLGA in these regions, than that noted globally[4, 18]. PLGA 
has a female predilection, with a female-to-male ration of 2.15:1[11, 19]. PLGA is most frequent 
in the 6th and 7th decades; the age of presentation peaks during the 6th decade[16, 20]. Cases in the 
literature vary from the 2nd to 10th decades of life, with the mean age at time of diagnosis being 
61.3 years of age[4, 11].  
 
1.1.1.2 Clinical Features  
 The clinical presentation of PLGA is non-specific and patients may or may not have 
symptoms[10, 13, 21]. Most commonly, this tumour presents as a firm, non-tender swelling of the 
palate, buccal or lip mucosa[21]. The lesion may exhibit pain, and infrequently, paresthesia[13, 
20]. Patients, on average, have symptoms for 27 months prior to diagnosis. Usually the mass lies 
within the submucosal plane, with intact and normal surface epithelium[20]. However, bleeding, 
ulcerations and telangectasias have been reported[21]. Furthermore, Chi and Neville recently 
described a rough stippled overlying mucosa feature, which was significantly found more often in 
PLGA tumours versus non-PLGA tumours[21].  
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The most common location to develop PLGA is on the palate, particularly at the junction 
of the hard and soft palate, where many minor salivary glands reside[11, 13, 16]. PLGA is also 
regularly found on the lips, as well as the buccal mucosa. Other intra-oral sites include: retromolar 
trigone, tongue, mandible, floor of mouth, and gingiva[10, 22]. Although rare, PLGA may occur 
in the major salivary glands; Sun et al.’s review of sublingual gland pathology in 2010 noted PLGA 
comprised 4.76% of tumours of the sublingual gland [23]. Even more rarely, PLGA may be found 
in extra-oral sites, including: the maxillary sinus, paranasal sinuses, lacrimal glands, orbit, ear, 
oropharynx/base of tongue, nasopharynx, larynx, uvula, breast and mammary gland, vulva, vagina, 
and skin[17, 24, 25]. Lesions have been found in the lungs as metastases, but also as primary 
lesions[15].  
PLGA is usually a slow growing tumour, but tumour size can vary from smaller to larger 
diameters, depending on location. The average tumour size at the time of presentation is 2.1 cm 
+/- 1.3 cm[11, 14, 16]. PLGA may be locally invasive, for example, palatal lesions will eventually 
invade the adjacent maxillary bone and sinuses[19]. Regional lymph node metastasis has been 
reported as high as 29%, but there is rarely hematogenous spread[26-28]. However, distant 
metastasis have reportedly been found in the lung and abdomen[29]. In their retrospective 
epidemiologic study, Patel et al. found a distant metastasis rate of 4.3%[11]. 
 
1.1.1.3 Imaging Features 
 PLGA exhibits variable radiographic characteristics; features are generally consistent with 
a slow growing, but aggressive tumour[8]. In a radiology journal, Potluri et al. presented a PLGA 
case with significant imaging findings; plain film investigations noted loss of maxillary bone and 
lack of sinus floor visualization, whereas computed tomography showed irregular cortical density, 
thinning of cortical plates, and mass effect with maxillary bowing and bony perforations[8]. Soft 
tissue findings on imaging noted hypervascularity and irregular contrast enhancement[8].  
 
1.1.1.4 Histopathology 
 PLGA is defined histologically as a well-circumscribed, non-encapsulated lesion with 
infiltrative borders[6, 11, 29, 30]. As the name “polymorphous” would suggest, this tumour 
demonstrates substantial histologic heterogeneity. Multiple growth patterns have been seen, 
including: solid, cribriform, trabecular, ductotubular, fascicular, papillary, glandular, cord-like, 
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and lobular[10, 14, 16, 20]. Importantly, more than one pattern may be visualized in the same 
tumour[9]. Furthermore, certain growth patterns, such as papillary, have been associated with more 
aggressive clinical behaviour, and higher rates of metastasis[26, 31]. 
Concentric growth patterns are often exhibited, with streaming columns of single-filed 
tumour cells, forming “whorls”, which appear targetoid in nature[12, 13]. The surface epithelium 
is usually not violated by tumour cells, and infiltrating nests or islands are less common, rather the 
tumour cells exhibit a “pushing” type of invasion[6, 13]. The tumour cells have been shown to 
invade salivary glands, muscle, connective tissue and bone; however, true skeletal muscle invasion 
is rare[6, 9].  
While, histomorphologically heterogeneous, PLGA displays nuclear homogeneity[11]. 
Nuclei are round, open-faced with dense and scattered nucleoli[13]. They demonstrate a classic 
“salt and pepper” nuclear form, with optically clear chromatin[8, 10, 14]. PLGA tumour cells 
contain scant to moderate cytoplasm, which may be eosinophilic, amphophilic, and infrequently 
contain oncocytes and mucin cells[6, 9, 16]. Langerhans cells have been seen in greater density 
with PLGA than other salivary gland malignancies, but not to a statistically significant level[32]. 
Again, as its title would suggest, PLGA demonstrates “low-grade” pathologic features. Cell 
necrosis and hemorrhage are infrequently encountered and mitosis are scant, if present[6, 10, 30, 
31]. Peri-neural and intra-neural invasion is seen; however, it does not correlate with more 
aggressive clinical behaviour[9, 16, 33]. Moreover, these tumours may display prominent 
vascularity, with perivascular invasion occasionally evident[16]. According to Ki-67 staining for 
proliferation indices of tumours, PLGA exhibits a relatively lower mean proliferation index 
(<6.4%), signifying a more indolent behaviour[25].  
In their epidemiologic study, Patel et al. revealed 37.2% of PLGA tumours were well-
differentiated/Grade I, and the remaining 62.8% of cases were moderately differentiated/Grade 
II[11]. Rare cases of histologic transformation from low-grade to high-grade have been 
reported[15, 26, 29]. This de-differentiation has correlated to more aggressive clinical 
behaviour[26].  
The diagnostic challenge PLGA poses is its morphologic resemblance and overlap with 
PA and ACC under the microscope[14, 34]. Specifically, all three of these neoplasms exhibit 
cribriform and tubular growth patterns[26]. Given the therapeutic and prognostic differences 
between these entities, it can be a significant pitfall to misdiagnose[9]. PA is composed of 
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proliferating epithelial, stromal, and myoepithelial cells which do not demonstrate the infiltrative 
pattern seen with PLGA; however, this is not always apparent, particularly in smaller biopsy 
specimens[22]. Myxochondroid and chondroid regions are seen commonly in PA, which can aid 
in differentiating from PLGA[22]. ACC is more common in major salivary glands, where PLGA 
is uncharacteristically found, so this is often useful in distinguishing between the two tumours[9]. 
Overlapping microscopic features seen with ACC and PLGA include: diffusely invasive borders, 
solid and cribriform growth patterns, and perineural invasion[35].  ACC characteristics that set it 
apart from PLGA are smaller cell size with less cytoplasm, hyperchromatic nuclei, coarser nuclear 
chromatin, and a higher nuclear-to-cytoplasmic ratio[6]. 
 
1.1.1.5 Diagnosis  
 The diagnostic work up for PLGA consists of a thorough history and physical examination, 
followed by appropriate diagnostic imaging. Many diagnostic modalities, such as sialography, 
radionucleotide scanning, and ultrasonography primarily have a role in pathology of the major 
glands[5]. Computed tomography (CT) and magnetic resonance imaging (MRI) are the favoured 
imaging modalities when investigating minor salivary glands[5]. Despite information gained from 
imaging studies, neoplastic growths of the salivary glands require histological tissue diagnosis. 
Fine-needle aspiration biopsy (FNAB) has a role in the diagnosis of major salivary gland 
pathologies; however, in minor salivary gland pathology it has little to no value[5]. The hallmark 
of diagnosis for PLGA remains adequate open tissue biopsy.  
 
1.1.1.6 Treatment and Prognosis 
 The treatment of choice for PLGA is surgery, with or without adjuvant radiotherapy[5, 11]. 
Surgery usually consists of wide local excision, with 1cm margins, or resection to the closest 
anatomic barrier[5]. In most cases, this will achieve local control of disease[15]. Depending on 
tumour size, reconstruction may be necessitated[30]. Neck dissection is generally not warranted 
in N0 disease; however, some advocate that if the primary site of PLGA is the base of tongue 
(BOT), it should be more seriously considered[17]. Others suggest therapeutic neck dissections 
should be limited to patients with clinical and radiographic evidence of positive cervical 
lymphadenopathy[19]. Furthermore, Pogodziski et al. and Gonzalez-Garcia et al. have 
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recommended no neck dissection unless a major resection and reconstruction has been 
planned[11]. 
 The role of radiotherapy for the treatment of PLGA remains uncertain[1, 5, 11, 30]. 
Adjuvant radiotherapy is considered in the setting of positive surgical margins; typical dosages are 
66Gy in 33 fractions for residual microscopic disease or 70Gy in 35 fractions for gross residual 
disease[30]. Furthermore, radiation may be considered as a primary treatment when patients are 
not suitable for surgery, when complete resection is not possible, or if the tumour is in close 
proximity to vital structures (e.g. parotid gland PLGA about the facial nerve)[17]. A cohort study 
by Castle et al. and a case series by Kimple et al. both demonstrated that post-operative 
radiotherapy had no significant change in patient outcomes[6, 10]. In the context of negative 
surgical margins, peri-neural involvement seen in PLGA does not warrant adjuvant radiotherapy, 
as it does not affect prognosis, and may be monitored[30]. Patel et al. reported that in all cases 
treated from 2001-2011, 77.9% had surgery alone, 2.6% had radiation alone, and 19.5% were 
treated with both[11]. Adjuvant chemotherapy has seldom been given, and requires further 
investigation as to its usefulness in the treatment of PLGA. 
 Staging of PLGA utilizes the American Joint Committee on Cancer (AJCC), Tumor, 
Nodes, Metastases (TNM) system. Patel et al. were able to obtain staging for 319/460 PLGA cases 
reviewed in their study; the tumours comprised the following stages: Stage I: 46.7%, Stage II: 
17.6%, Stage III: 5.6%, and Stage IV: 11.9%[11]. Further classification using TNM was also 
reported. Tumour status,  T1: 48%, T2: 20.1%, T3: 4.4%, T4: 10.0% and Tx: 17.6%, node status, 
N0:88.4%, N1:3.4%, N2: 1.6%, and Nx:6.6%, and metastases status, M0: 93.1%, M1: 1.6%, and 
Mx: 5.3%[11]. 
 Recurrence rates for PLGA vary in the literature, but have been reportedly as high as 
33%[11, 36]. Other documented ranges for local recurrence have suggested 9-17%[2, 3, 21]. 
Recurrences of PLGA have been found in the context of negative surgical margins[20, 24]. It has 
also been reported that females are more likely to experience recurrent disease[6]. Late recurrences 
are not uncommon, with reports of recurrent PLGA arising anywhere between 1 and 24 years[10, 
30]. The average time to present with recurrence of disease is 7.2 years[6, 17]. In their case series, 
Kimple et al. stated 50% of recurrences happened by 35 months, and they also went on to note of 
the recurrent PLGA cases studied, 54% demonstrated local recurrences, 32% were nodal, and 8% 
were distant[10]. Rates of recurrence with surgical resection alone, compared to surgical resection 
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with adjuvant radiotherapy have not demonstrated any significant difference[6, 10]. 
Histologically, recurrent disease appears more aggressive, with evidence of papillary 
histomorphology, increased mitotic figures, and overall “intermediate-grade adenocarcinoma”[11, 
17]. Interestingly, peri-neural invasion has not been linked to increase rates of recurrence in 
PLGA[11]. The potential for delayed recurrence, and recurrent nodal disease, warrants prolonged 
clinical follow up; recommendations for at least 15 years of follow up have been suggested[20, 
31].  
 Overall, the prognosis for PLGA is excellent[13, 21]. The 5 and 10-year disease specific 
survival (DSS) has been reported as 98.6% and 96.4%[11]. Based on treatment modality, 10-year 
DSS survival notes 98% for surgery alone, 90.9% for surgery, with adjuvant radiotherapy, and 
75% for radiotherapy alone[11]. 
 
1.1.1.7 PLGA variant, Cribriform adenocarcinoma of the tongue and minor salivary glands 
 Recently, a variant of PLGA has been noted in the literature, thought to differ in clinical 
location, behaviour and histopathology[12]. Termed “Cribriform Adenocarcinoma of the Tongue 
and Minor Salivary Glands” (CATMSG), it is currently regarded as a “provisional entity” by the 
WHO[33]. Originally, Michal et al. described this tumour as Cribriform Adenocarcinoma of the 
Tongue in 1999; however, with more cases reported, the term has now expanded to include the 
minor salivary glands[26]. Presently, there are 41 well-documented CATMSG cases in the 
literature, but it remains controversial whether CATMSG and PLGA remain separated entities or 
whether they are variants of one tumour spectrum[26, 37].  
CATMSG occurs primarily in adults, with one adolescent case report by Takhar et al[12, 
37]. Unlike PLGA, CATMSG shows no gender predilection[37]. Furthermore, CATMSG 
demonstrates a more aggressive clinical behaviour, having higher rates of local metastatic spread 
(61.2%)[12, 33]. Michal et al. postulate that if CATMSG was considered a separate entity, the rate 
of PLGA metastasis to regional lymph nodes would be significantly lower[33]. Distant metastases 
have not been reported to date[38]. Although more patient lymph node metastases at the time of 
presentation, the tumour remains indolent overall, with a favourable prognosis[33].  
Histologically, CATMSG shares characteristics of cribriform, microcribriform, and solid 
patterns with PLGA; however, it can exhibit clefts and tumour nests resulting in a glomeruloid 
appearance[33, 38]. Moreover, the nuclei overlap, are pale, optically clear, with a ground glass 
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appearance, making this tumour variant quite histologically similar to papillary thyroid 
carcinoma[38]. Rarely, psamomma bodies may be seen[33]. Importantly, these tumours stain 
negatively for thyroglobin and TTF-1[33, 38]. The immunohistochemical profile of CATMSG has 
otherwise been variable; positive staining has been noted in cytokeratin markers (AE1-3, CAM5.2, 
CK7, CK8, CK18), S-100, SMA, calponin, and vimentin. C-kit, p16, cyclin D1, p53, and CK19 
have been inconsistent. Lastly, the Ki-67 index has usually been low[33].  
 
1.1.1.8 Biomarkers associated with PLGA 
 In an effort to improve diagnostic accuracy in salivary gland pathology, many groups have 
examined the immunohistochemical profile of PLGA. The summary of biomarkers studied to date 
are presented in Table 1.1.1.8.1. 
1.1.1.8.1 Ki-67  
 Ki-67 is a cell cycle-associated antigen which is useful as a biomarker for cell proliferation, 
and is therefore, thought to have use as a prognostic indicator in salivary gland malignancies[35, 
39]. Ki-67 is only expressed by proliferating cells, and has its peak expression in M phase of the 
cell cycle[39]. The Ki-67 index for PLGA is usually <6.4%, with mean values 1.6%-2.4%[3, 37]. 
In comparison to other malignant salivary gland tumours, Skalova et al. and Vargas et al. reported 
PLGA had a significantly lower Ki-67 index than ACC[14, 30]. Beltran et al. also demonstrated a 
lower Ki-67 index in PLGA versus ACC; however, this was only “suggestive statistical 
significance”[35]. Other groups have noted no significant difference in Ki-67 index between ACC 
and PLGA and/or an increased index in PLGA[7, 29, 35]. Higher Ki-67 indices have been seen 
with de-differentiated PLGA tumours, and therefore, a ki-67expression analysis may be a useful 
tool in identifying this high-grade variant of PLGA[29]. In their 2011 study, Falchete do Prado et 
al. examined Ki-67 and fatty acid synthase expression in salivary gland tumours, noting greatest 
fatty acid synthase expression in PA and higher Ki-67 index in salivary gland malignancies[39]. 
MEC showed the highest Ki-67 index, followed by ACC and PLGA; there was no correlation 
between fatty acid synthase expression and Ki-67 index[39].   
1.1.1.8.2 C-kit (CD117) 
 C-kit is a proto-oncogene that encodes a transmembrane receptor tyrosine kinase and is 
shown to be overexpressed in ACC[3, 35]. In their clinicopathologic study, Schwarz et al. cited 
their most remarkable finding was that c-kit expression is primarily absent in PLGA, when 
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compared to ACC[7]. Beltran et al. found PLGA had significantly weaker staining for c-kit in 
PLGA versus ACC[35]. Moreover, Rooper et al. presented studies demonstrating diffuse positive 
c-kit staining in ACC and c-kit negative staining in PLGA; however, they cited other studies noting 
no significant difference between the two malignancies[14]. 
1.1.1.8.3 p63+/p40- 
 Recently, a p63+/p40- immunohistochemical staining panel has been argued as a valuable 
tool for diagnosing PLGA. The immunohistochemical marker p63 is normally expressed in the 
basal layer of stratified epithelium, myoepithelial cells, and the malignancies that proliferate from 
these cells[14]. It’s isotype, p40 is a more specific marker of basal stratified epithelial and 
myoepithelial differentiation[14]. To date, p63 has not shown diagnostic use for PLGA, as despite 
lack of myoepithelial proliferation in this tumour, it stains diffusely positive for p63; however, 
Rooper et al. demonstrated that PLGA stained negatively for the more specific p40 isotype[14]. 
They concluded that the p63+/p40- phenotype was 100% sensitive and 93% specific for PLGA, 
showing diagnostic promise[14]. 
1.1.1.8.4 p53 
p53 is a tumour suppressor protein encoding for a nuclear phosphoprotein, controlling cell 
proliferation[40]. PLGA has shown variable p53 staining in the literature as well[9]. Some studies 
demonstrate little p53 staining in PLGA, whereas other groups report PLGA shows the highest 
expression of p53 out of all salivary gland neoplasms[34]. 
1.1.1.8.5 S-100 
The S-100 protein family is a group of low molecular weight proteins, with calcium binding 
sites and are expressed by a number of cell types[41]. Furthermore, these proteins have been 
implicated in inflammatory process regulation, as well as the development of metastasis in several 
cancers[41]. S-100 protein stains have been well-examined in salivary gland neoplasia[9]. The 
majority of PLGA are S-100 positive, demonstrating diffuse staining[6, 42]. In contrast, ACC and 
adenocarcinoma NOS both show weaker S-100 protein staining; however, ACC staining may be 
variable[9, 42].  
1.1.1.8.5.1 Mammaglobin and S-100 co-expression 
To improve the diagnostic value of S-100 in salivary gland neoplasms, Patel et al. studied 
its co-expression with mammaglobin, a glycoprotein and biomarker used in breast cancer[43]. 
They concluded that 100% of PLGA cases stained positive for mammaglobin, and 93% of PLGA 
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cases stained positive for S-100[42]. Ultimately, 60% of PLGA cases met the staining criteria for 
co-expression of S-100 and mammaglobin, whereas only 13.3% cases of ACC met such 
criteria[42]. 
1.1.1.8.6 CD43 
 CD43 is a transmembrane surface protein, normally expressed in T lymphocytes, natural 
killer cells, and myeloid cells[44]. Weak expression of CD43 has been found in epithelial cells, 
synovial cells, fibroblasts and chondrocytes[44]. CD43 has been found to be expressed more 
strongly in ACC when compared to PLGA[13, 21].  
1.1.1.8.7 Osteopontin (OPN), CD44, integrin avb3 
 OPN is an acidic phosphoglycoprotein, which interacts with two ligands, cell receptors 
CD44 and integrin avb3, and is expressed in various tumours[45]. Increased expression of OPN is 
thought to be involved with malignant tumour invasion and metastasis[45]. Fok et al. studied the 
expression of osteopontin, as well as it’s ligands in salivary gland tumours, concluding that PLGA 
and ACC demonstrate increased OPN expression compared to benign salivary gland tumours and 
normal salivary gland tissue (NSGT)[45]. Furthermore, CD44 expression was reduced in PLGA, 
which they postulated could suggest a less aggressive tumour behaviour, as CD44 interacts with 
OPN to promote metastasis[45]. Integrin avb3 showed scattered staining in PLGA[45]. 
1.1.1.8.8 Cytokeratins, Vimentin 
 Cytokeratins are keratin-containing intermediate filaments, which are expressed in 
epithelial tissue and may be divided into low and high molecular weight keratins[46].  Cytokeratins 
have shown positive staining in PLGA, specifically de Araujo et al. noted CK8 and CK18 to have 
increase expression in PLGA[47].  
Vimentin is an intermediate filament protein that is expressed by mesenchymal cells[47]. 
PLGA has demonstrated positive vimentin staining in various studies, and in contrast, ACC shows 
weaker staining[30]. Darling et al. reviewed the literature for the immunohistochemistry staining 
profile of PLGA, and concluded that vimentin was the only immunohistochemical marker to 
reliably differentiate PLGA from ACC[9].  
1.1.1.8.9 Carcinoembryonic antigen (CEA) 
 CEA is a glycoprotein which functions in cell adhesion. CEA has demonstrated expression 
in ACC; however, the CEA expression profile has varied with PLGA[9, 30]. Several groups have 
shown PLGA stains negatively for CEA, whereas other groups have reported some staining 
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variability, thus CEA is not uniformly negative in PLGA and has decreased diagnostic value[9, 
29]. 
1.1.1.8.10 Smooth muscle actin (SMA), muscle specific actin (MSA), galactin-3, cyclin D1, 
glial fibrillary acid protein (GFAP), epithelial membrane antigen (EMA) 
 Other biomarkers have been less reliable in differentiating between salivary gland tumours. 
Multiple studies have shown that ACC demonstrate increase expression of smooth muscle actin 
(SMA), and increased nuclear expression of galectin-3 and cyclin D1, as compared to PLGA[10, 
21, 30]. GFAP staining has been reported as both negative and positive in PLGA; its expression is 
relatively higher in PA, whereas ACC’s expression of GFAP is unknown[9, 14].  EMA stains 
positive in both ACC and PLGA[9]. MSA stains moderately positive in ACC; however, in PLGA 
the stain is negative to weak[9].   
1.1.1.8.11 Maspin and Mini-chromosome maintenance protein (MCM2) 
 Maspin is a mammary serine protease inhibitor, that functions to prevent apoptosis and 
decrease cell invasion, and may have a role in preventing angiogenesis[48]. MCM2’s are mini 
chromosome maintenance proteins, which are paramount for DNA replication and therefore, have 
use as markers for cell proliferation[48]. In 2011, Ghazy et al. studied the expression of maspin 
and MCM2 in salivary gland tumours, and specifically wanted to determine if their expression 
correlated to lymph node metastasis[48]. Salivary gland tumours, including PLGA and ACC, 
stained positively for both maspin and MCM2 to a variably degree, but ACC showed a higher 
proliferation profile versus PLGA. There was no significant correlation between maspin and 
MCM2 expression and regional metastatic disease[48].  
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Table 1.1.1.8.1. Biomarkers studied in PLGA  
Biomarker Definition Indicates  PLGA 
value 
Significance Clinical use 
Ki-67 Cell 
cycle-
associated 
antigen 
Cell 
proliferation 
<6.4% Index 
PLGA<ACC<M
EC 
“only 
suggestive 
statistical 
significance” 
C-kit 
(CD117) 
Proto-
oncogene 
Increase in 
transmembrane 
receptor 
tyrosine kinase 
Absent Overexpressed in 
ACC 
Differences 
may or may 
not be 
significant 
p63+/p40- IHC 
markers 
for tumour 
proteins 
Staining 
p63:  
basal layer 
p40: 
myoepithelial 
differentiation  
PLGA 
stains + 
for p63 
and – for 
p40 
p63+/p40- 
phenotype 100% 
sensitive and 93% 
specific for 
PLGA 
Diagnostic 
promise in 
PLGA 
p53 Tumour 
suppressor 
protein 
Controls cell 
proliferation 
Variable p53 
overexpression 
seen in 38% of 
PLGA  
Limited 
S-100 Low 
molecular 
weight 
protein 
Present in neural 
crest cells, 
chondrocytes, 
adipocytes, 
myoepithelial cells, 
macrophages, 
Langerhans cells, 
dendritic cells, 
keratinocytes  
Majority 
positive 
PLGA stains 
positive and 
diffusely vs ACC 
(may be variable) 
Limited  
Mammagl-
obin &  
S-100 
Mammaglobin
: glycoprotein Present in variable cells 
Majority 
positive 
for both 
PLGA: 60% co-
expression 
ACC: 13% co- 
expression 
Limited  
CD43 Trans-membrane  
surface protein 
Present in T 
lymphocytes, 
natural killer 
cells, myeloid 
cells 
Variable Expressed more 
strongly in ACC 
vs PLGA 
Limited 
Osteopontin, 
CD44, 
integrin 
avb3 
OPN: 
phosphoglyco
protein 
CD44 and 
integrin 
avb3: 
ligands for 
OPN 
OPN involved 
in malignant 
tumour 
invasion 
OPN 
expression 
increased; 
CD44 
reduced; 
integrin 
avb3 
scattered  
PLGA and ACC 
have increased 
OPN expression 
vs NSGT 
Limited 
Cytokeratin
Vimentin 
Cytokerati
n: Keratin 
containing 
intermediate 
CK: Expressed 
in epithelial 
tissues 
Positive 
staining; 
CK8 and 
Vimentin positive 
in PLGA, and 
weak in ACC 
Vimentin 
staining may 
reliably 
differentiate 
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filament 
proteins 
Vimentin: 
intermediate 
filament 
protein 
V: expressed in 
mesenchymal 
cells 
CK18 
increased. 
Positive 
staining 
between 
PLGA and 
ACC 
CEA Glycol-
protein 
Functions in cell 
adhesion; 
biomarker for 
colon cancer and 
ovarian cancer 
Variable  CEA stains 
positive in ACC, 
but is decreased 
and/or variable in 
PLGA 
Limited 
SMA, 
MSA, 
galactin-3, 
cyclin D1, 
GFAP, 
EMA 
Ubiquitous 
proteins 
Found in 
muscle and 
non-muscle 
cell tissues 
SMA: 
decreased 
MSA: 
decreased 
GFAP: 
variable 
EMA: 
increased 
 
ACC: increased 
expression of 
SMA, galectin-3 
and cyclin D1 
versus PLGA 
Limited 
Maspin & 
MCM2 
Maspin: 
mammary 
serin protease 
inhibitor 
MCM2: 
Mini 
chromosome 
maintenance 
proteins 
Maspin:  
prevents apoptosis 
and decreases cell 
invasion 
MCM2:  
Marker for cell 
proliferation due to 
role in DNA 
replication 
Variable PLGA and ACC 
variably stain for 
maspin and 
MCM2; ACC 
increased cell 
proliferation 
profile vs PLGA 
Limited  
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1.1.1.9 Genetic studies in PLGA 
1.1.1.9.1 Translocation, t(11;19) 
 Genetic translocation t(11;19) has been identified in MEC and was not found to be present 
in PLGAs[30].  
1.1.1.9.2 Gene fusions 
1.1.1.9.2.1 MYB-NFIB 
 The MYB-NFIB gene fusion has been identified in ACC, and therefore, Persson et al. 
chose to investigate this fusion in PLGA[34]. Their 2011 study revealed the MYB-NFIB fusion 
was only present in 1 of 9 PLGA cases; they felt this highlighted the diagnostic difficulties in 
separating PLGA from ACC[34]. Ultimately, they concluded the PLGA genome was genetically 
stable[34].  
1.1.1.9.2.2 ARID1A-PRKD1 and DDX3X-PRKD1 
ARID1A and DDX3X encode proteins that are involved in DNA repair, and loss of their 
function would result in aberrant DNA repair[26]. Furthermore, ARID1A has already been 
identified to have a role in gynecologic malignancies[26]. The PRKD1 gene encodes a kinase 
protein, which has been implicated in a variety of malignant processes, including: colorectal, 
breast, esophageal, laryngeal, and others[26, 27, 37]. Moreover, PRDK1 kinases partake in signal 
transduction, trafficking, migration, differentiation and proliferation of cells, as well as cell 
adhesion[28, 37]. In 2014, Weinreb et al. searched for novel gene fusions in 2 cases of PLGA and 
2 cases of CAMSG using next generation RNA sequencing[26]. Fusion ARID1A-PRKD1 was 
found in one CAMSG case, and a DDX3X-PRKD1 fusion was located in the other CAMSG 
case[26]. No fusions were found in the classic PLGA cases[26]. Weinreb et al. were able to 
conclude that recurrent genetic rearrangements of PRKD1-3 and specific gene fusions ARID1A-
PRKD1 and DDX3X-PRKD1 are associated with PLGA, in particular the CAMSG variant[26].  
1.1.1.9.3 PRDK1 hotspot mutation 
 In their 2014 multi-centre study, Weinreb et al. identified the PRDK1 hotspot mutation 
encoding p.Glu710Asp in PLGA[27]. By sequencing the genome of 3 PLGA cases, two 
heterozygous single nucleotide variants were found in the PRDK1 gene, resulting in the same 
amino acid substitution and consequential increased PRKD1 activity[27]. Subsequently, each 
PLGA in their tumour bank were examined for this mutation, and it was present in 72.9% of 
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cases[27]. The hotspot mutation was significantly associated with metastasis-free survival and the 
group concluded it may offer a neoplastic advantage to PLGA tumour cells[27]. 
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1.2 Kallikreins (KLKs) 
Human kallikreins are secreted serine proteases, which demonstrate a range of physiologic 
and pathologic functions[49]. They are one of 178 human serine proteases, specifically belonging 
to the S1A subfamily[50]. Human kallikreins are divided into two categories: plasma kallikrein 
(KLKB1) and tissue kallikreins (KLK1-15)[51].  
1.2.1 Plasma Kallikrein 
KLKB1 is encoded by a single gene on chromosome 4q35, which consists of 15 exons and 
does not share similarities with the tissue kallikrein family[51, 52]. Mature plasma kallikrein 
functions as a major component of the plasma kallikrein-kinin system (KKS), releasing lysyl-
bradykinin from high-molecular weight kininogen[53]. The KLKB1 gene consists of 15 exons and 
does not share similarities with the tissue kallikrein family[51, 52].  
1.2.2 Tissue Kallikreins 
1.2.2.1 General Overview 
Human tissue kallikreins are a single family of 15 highly conserved trypsin and 
chymotrypsin-like serine proteases[54-56]. KLK1-15 are mapped to chromosomal locus 19q13.4 
(Figure 2.1.2.1), which is the richest gene-containing chromosome, containing 261558 base 
pairs[50, 53, 57, 58]. Furthermore, KLKs are encoded by the largest contiguous cluster of protease-
encoding genes in the human genome, and uniquely, they are not interrupted by any other non-
KLK genes[49, 50, 57, 59, 60]. KLK genes are arranged closely, with as little as 1.5kb-32.5kb 
between genes, and specific KLK gene lengths range from 4-10kb[50, 53]. The KLK tandem 
cluster of genes is flanked by the testicular acid phosphatase gene (ACPT) on the centromeric end 
and by the cancer associated gene (CAG), as well as Siglec-9 on the telomeric end[50].  
KLK genes share many similar structural features including: exon and intron organization, 
conservation of intronic intervals, and exon lengths[60]. KLK gene transcripts code for a single 
chain serine protease pre-proenzyme of a fixed length, between 248 and 293 amino acids[50, 57]. 
The KLK genes and translated proteins share a high degree of homology; KLK proteins have an 
amino acid sequence homology of ~40-80%, with KLK2 and KLK3 having the highest degree of 
similarities[50]. A common characteristic of KLK proteins is their signal peptide motif (16-57AA), 
which conveys that all KLK proenzyme forms are to be secreted[50]. All KLKs have 10-12 
cysteine residues, which are thought to form disulfide bones, important to maintain the correct 
conformation of the protein[50]. 
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Figure 1.2.2.1 The human tissue kallikrein gene cluster. This figure was originally published 
in Journal of Biological Chemistry. Sotiropoulou G, Pampalakis G, Diamandis EP. Functional 
roles of human kallikrein-related peptidases. 2009; 284(48): 32989-94. The figure is being 
reproduced for educational purposes only and not for any commercial use. Figure is included in 
the M. Sc. dissertation with attribution. 
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Ultimately, KLKs are secreted serine proteases with a diverse expression and many 
physiologic, as well as pathologic roles[49]. Moreover, KLKs are versatile signalling 
molecules[60]. While they demonstrate expression in a wide variety of tissues, KLKs are primarily 
expressed by secretory epithelial cells within glandular epithelia of many organs[49, 53, 56, 59]. 
1.2.2.2 Historical Development  
The first kallikrein, KLK1, was identified in the 1930s by Kraut, Frey, and Werle[49]. The 
group termed the proteolytic enzyme “kallikreas”, the Greek word for pancreas, due to its high 
pancreatic expression[49, 61]. It wasn’t until 40 years later that “prostate specific antigen”, PSA, 
was discovered as an identification agent in semen by forensics scientists[49]. It was later renamed 
KLK3[62]. Initially, it was believed that KLK1-3 were the only members of the KLK family; but 
in the late 1990s, 12 novel KLK genes were discovered through examination of the whole genetic 
locus[49, 53].  Several groups reported other genes mapping to 19q13.4, and ultimately, all 15 
KLK members were cloned[53]. KLK15 was the last member to be cloned, and this was completed 
in 2001[49, 53]. A detailed map of the KLK gene locus was created by Borgono and Diamandis 
in 2004[57, 63, 64].  
Anecdotally, kallikreins were divided up into classical and non-classical groups[57]. 
KLK1-3 were denoted as classical, as these were the first members of the KLK family 
discovered[53]. The non-classical group contains KLK4-15, as they were identified at a later 
date[57, 63].  
 With significant advancements in the development of the kallikrein genetic family, a 
comprehensive nomenclature system was proposed in a 2006 review by Lundwall et al[61]. KLK1 
was the only KLK gene to retain the “kallikrein” name, denoted as kallikrein 1[63]. However, as 
the remaining proteins in the KLK family do not display kininogenase activity, KLK2-15 were 
termed “kallikrein-related peptidases”, followed by their genetic number symbol[61, 63]. For 
example, KLK2 was re-named kallikrein-related peptidase 2[61]. This classification system also 
differentiates between gene and protein denotation; genes are written in italicized text (e.g. KLK1), 
whereas proteins are written in standard text (e.g. KLK1)[61]. 
1.2.2.3 Kallikreins as proteases at the genomic, mRNA, and protein level 
Kallikreins are serine proteases, specifically belonging to the S1A subfamily of serine 
proteases[50]. They may display trypsin or chymotrypsin-like activity, or both[54, 65]. KLKs 
share characteristic features, some of which overlap with all serine proteases, and those that are 
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unique to the KLK family. KLKs demonstrate invariant residues, they have an active site catalytic 
triad (His57, Asp102, Ser195), and a conserved Gly, which stabilizes the peptide bond during 
hydrolysis[57]. Unique features of the KLK family were well documented by Yousef and 
Diamandis in their 2002 comprehensive review of KLKs as cancer biomarkers. These include: i) 
KLK genes are formed by 5 codons, with the first codon always containing a 5’ untranslated 
region, followed by a methionine start codon about 50bp away from the previous exon, and lastly, 
a stop codon about 156bp away from the beginning of the last coding exon; ii) the catalytic triad 
(His57, Asp102, Ser195) is conserved, histidine is always placed at the end of the second coding exon, 
the aspartate is in the middle of the third coding exon, and the serine at the beginning of the fifth 
coding exon; iii) the substrate binding pocket amino acid is either aspartate, representing trypsin-
like specificity (KLK1,2,4,5,6,8,10, 11,12,13,14,15), or it is another amino acid, representing 
chymotrypsin activity (KLK3,7,9) or other activity; iv) KLK proteins contain 10-12 cysteine 
residues, with conserved positioning, forming 5-6 disulfide bonds; v) KLKs are under steroid 
hormone control[51, 53, 66]. 
Many KLK genes exhibit copy number variations, which result from the use of alternative 
and multiple promotors, based on their 5’untranslated regions[60, 67]. Furthermore, the 15 
transcripts from the KLK genes may be alternatively spliced, producing many different mRNA 
variants, thought to encode truncated proteins[49-51, 53]. The most common alternative splicing 
events are skipped exons and exon extension, with exon truncation and intron retention 
succeeding[49]. KLK3 is known to have at least 10 distinct mRNA variations, resulting from 
alternative splicing[49]. Following an alternative splicing event, the mRNA variant may be 
translated into functionally distinct proteins[49]. For example, KLK7 demonstrates mRNA 
variants with different patterns of tissue localization[67]. Furthermore, these variants may have 
roles in pathologic disease, and malignancies, as the consequential protein may have additional 
functional roles, may lack classic KLK properties, or may be rendered non-functional[49]. It has 
been stated that the product of alternative splicing most often encodes inactive KLK isoforms[60]. 
The involvement of serine proteases in cascade pathways has been well established; 
substrates of serine proteases are often other serine proteases, which are activated from their 
inactive form, into an active protein[53]. An example is the coagulation cascade. Similarly, 
kallikreins are thought to participate in a variety of complex proteolytic cascade pathways, 
involved in the regulation of physiologic and pathologic processes[54]. These include: semen 
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liquefaction, skin desquamation, neurodegeneration and tumour promoting or inhibiting 
effects[49]. The hypothesis that KLKs participate in proteolytic cascades is supported by the co-
expression of numerous kallikreins in the same tissue, and the evidence that some kallikreins 
activate each other[53]. For example, KLK3 can be activated by KLK15 and KLK4 has been 
shown to activate KLK3[53]. Furthermore, KLKs may participate in proteolytic cascades that 
involve nonkallikrein serine proteases; KLK3 can inactivate the N terminal fragment of the 
parathyroid hormone related protein[53].  
1.2.2.4 Activation of tissue kallikreins 
The activation of KLK enzymes occurs through a complex proteolytic cleaving process, a 
cascade referred to as the “KLK Activome” (Figure 2.1.2.2)[60]. Coordinated activation occurs 
through this complex network and results in the activation of KLK enzymes that go on to regulate 
normal and pathological processes[60]. As noted above, KLK genes are transcribed into a pre-pro-
enzyme, which is a zymogen, as it is inactive in this form; this is single chained and of fixed AA 
length[57]. This pre-pro-enzyme goes on to be proteolytically processed to an enzymatically 
inactive pro-KLK, and these are secreted into the extracellular space by cleaving an amino-
terminal signal peptide[57]. Ultimately, the pro-KLK is activated to a mature peptidase 
extracellularly by cleaving the amino-terminal propeptide[51, 60]. KLKs may be auto-activated, 
activated by another KLK, or activated by a different protease altogether[57, 63]. Proteases 
implicated in the activation of KLKs include matrix metallopeptidases and the proteases of the 
thrombostasis axis[59]. 
1.2.2.5 Regulation of kallikreins 
 The regulation of kallikreins occurs at various levels of their processing and activation into 
functional proteases. This includes transcriptional, post-transcriptional and/or post-translational 
levels, and therefore, resultant aberrations in their expression are seen with dysregulation at any of  
these steps[60]. Kallikreins show differential expression, which may be tissue dependent, and 
while some regulatory factors are unknown, others have been well studied[53, 66]. 
 At the transcription level, steroid hormones are considered to be the primary regulatory 
mechanism of KLK gene expression[51, 64, 68]. Moreover, epigenetic mechanisms, specifically 
DNA methylation is also thought to have an important role in KLK transcription[60]. 
 It has been well established that in endocrine tissues (e.g. breast, prostate, ovarian tissues), 
all KLK expression is regulated by specific hormones including: androgens, estrogens, progestins,  
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Figure 1.2.2.2 KLK Activome and regulatory KLK cascades in normal physiology and 
disease. This figure was originally published in Biochimica et Biophysica Acta (BBA) – Reviews 
on Cancer. Pampalakis G, Sotiropoulou G. Tissue kallikrein proteolytic cascade pathways in 
normal physiology and cancer. 2007; 1776 (1):22-31. The figure is being reproduced for 
educational purposes only and not for any commercial use. Figure is included in the M. Sc. 
Dissertation with attribution. 
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glucocorticoids, and mineralcorticoids[56, 66, 69]. This is mediated directly by nuclear receptors, 
which bind ligands, translocate to the nucleus and bind to cis-acting DNA sequences, known as 
hormone response elements (HRE)[69]. These are found in the promoter/enhancer regions of many 
KLK genes, including KLK2 and KLK3, and transcription is stimulated[66]. Indirect modulation 
of transcription does not involve HRE, rather it involves a hormone-receptor complex interacting 
with various transcriptional factors, resulting in trans-transcription[69].  
Of note, the centromeric and telomeric KLK groups, KLK1-4 and KLK13-15 respectively, 
are primarily upregulated by androgens, and the central KLK group (KLK5-12) is primarily 
upregulated by estrogens[53]. Interestingly, the same KLK gene may be upregulated by two 
separate hormones, in site-specific tissue; in prostate and breast cancer cell lines, KLK4 is 
upregulated by androgens, whereas in endometrial cell lines, it is upregulated by estrogens[53, 69]. 
An exception is found in KLK1, which does not demonstrate hormone control in various tissues, 
specifically uterine, renal, and salivary gland tissues[50]. 
Vitamin D signalling has also been well established as a transcriptional regulatory 
mechanism of KLK expression[60]. Vitamin D3 upregulates KLK6 in various cancer cell lines, 
including: head and neck, prostate, colon[66]. In normal keratinocytes, vitamin D3 has 
demonstrated regulatory control over KLK10, in addition to KLK6, and thus, they have both been 
implicated in skin carcinogenesis[55, 66].  
Retinoic acid also contributes to the regulation of KLK genes. This may be accomplished 
through a retinoic response element alone, or in combination with a series of receptors[66]. 
Retinoic acid demonstrates differential regulation of kallikreins; KLK10 is upregulated in breast 
cancer cells; however, KLK2 and KLK3 is downregulated in prostate cancer cells[66]. 
Epigenetic mechanisms demonstrate transcriptional regulation of KLK gene expression. 
DNA methylation modifications may silence certain KLK genes in cancer processes[60]. For 
example, hypermethylation is thought to silence KLK10 in both ovarian and prostate cancer[69, 
70]. Furthermore, DNA methylation of the KLK genome has been shown in the aberrant KLK 
expression in acute lymphoblastic leukemia (ALL), prostate and breast cancer cells[51]. In ALL 
and breast cancer, hypermethylation of exon 3 significantly down regulates KLK10[69]. 
A body of evidence suggests there is post-transcriptional regulation of KLKs by 
microRNAs (miRNAs), which are small non-coding RNAs that regulate gene expression[70]. 
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These miRNAs function by partially annealing to their target RNA sequence, and decreasing 
protein translation via an RNA-induced silencing complex (RISC)[70]. It has been observed that 
one miRNA may target several KLK regions, therefore, may control multiple KLK proteins 
simultaneously, silencing translation[70].  
Another element of KLK regulation is at the post-translational level. Protease activation is 
an irreversible process and therefore, the regulation of proteolytic cascades is tightly controlled[58, 
64]. Several mechanisms have been implicated in the prevention of unwanted enzymatic 
degradation of proteins, which include: zymogen activation, internal cleavage, and endogenous 
inhibitors[64, 69]. Zymogen activation has been described previously, and occurs through a 
diverse proteolytic cleavage cascade[69]. It should be noted that all pro-KLKs, with the exception 
of KLK4, require the activity of trypsin-like serine protease for activation, and these include: 
trypsin, enterokinase, trypsin-like KLKs, and auto-activation[69]. Internal cleavage has been noted 
as a mechanism of inactivation in 6 of the 15 mature KLKs; cleavage occurs at the activate protease 
either by autolysis or alternative proteases, resulting in degradation of the KLK protein[69]. 
Endogenous inhibitors known to regulate serine proteases, such as KLKs, include: serpins and 
alpha-2 macroglobulin, both plasma inhibitors[69]. Serpins interact with KLKs in complex 
pathways to deform and inactivate serine protease, whereas alpha-2 macroglobulin prevents other 
proteases from binding the KLK by steric hindrance[69]. Microenvironments contribute to KLK 
activity regulation, including the presence of certain ions and the pH of the tissues[58]. High 
concentration of Zn ions in prostate tissue inhibits enzymatic activity of many KLKs, whereas 
lower Zn ion concentrations are found in prostate cancer, contributing to higher KLK activity[51]. 
1.2.2.6 Physiologic function of kallikreins 
 KLKs are expressed in a wide variety of tissues in the body, including, but not limited to 
pancreas, heart, lung, CNS, salivary glands, thyroid, breast, testis, ovaries and prostate[53, 56, 57, 
71]. An exhaustive list of tissues expressing KLKs is presented in Figure 2.1.2.3, adapted from 
Yousef and Diamandis’ 2001 review of KLKs[71]. Notably, it also demonstrates that KLKs may 
be co-expressed in normal tissues, but that this expression occurs at different levels[60, 71]. The 
physiologic roles of KLKs have been best established for KLK1-3[53]. Physiologic processes that 
KLKs are involved in include: tissue kallikrein-kinin system, skin desquamation, innate immunity, 
semen liquefaction, enamelogenesis, and degradation/remodeling of the extracellular matrix 
	 24	
(ECM)[53, 55]. Additionally, KLKs help regulate blood pressure, and are involved in electrolyte 
balance in ECM remodeling, prohormone processing, and neural plasticity[49]. 
KLK1 
The highest expression of KLK1 is found in the pancreas, kidney, and salivary glands; it has also 
been found in sweat glands, pituitary gland, intestines, uterus, prostate, testis, breast, placenta, and 
neutrophils[50, 71]. The primary function of KLK1 is its involvement in the tissue KKS as a 
kininogenase enzyme, releasing lysyl-bradykinin from low-molecular weight kininogen[53]. It is 
also known to cleave pro-insulin, pro-renin, LDL, the precursor for atrial natriuretic factor, 
vasoactive intestinal peptide, procollagenase, and angiotensinogen[50]. 
KLK2 
KLK2 shows highest expression in the prostate, and is also found in breast, salivary gland, and 
thyroid tissue[71]. It plays a role in seminal plasma liquefaction; however, it is a smaller role than 
that of KLK3[53, 57]. 
KLK3 
The prostate is where KLK3 is most highly expressed, but it is also found in breast, thyroid, 
tracheal, and lung tissues[71]. KLK3 has been found in several fluids apart from its high 
concentration in semen, including breast cyst fluid, nipple fluid, milk of lactating women, and 
amniotic fluid[53]. KLK3 has a primary role in seminal plasma liquefaction, and through 
hydrolysis, liquefies the seminal plasma clot after ejaculation[53, 57]. 
KLK4 
The highest expression of KLK4 is found in the prostate; it has also been found in breast, thyroid, 
testis, uterine, adrenal, colon, and spinal cord tissues[71]. Furthermore, KLK4 is thought to have 
a primary role in the biologic function of enamel maturation and tooth development[50]. 
Specifically, KLK4 degrades enamelin to allow for apatite growth[50].  
KLK5 
The highest expression of KLK5 is found in breast, brain, testicular, and skin tissues; it has also 
been found in salivary glands, thymus, CNS, prostate, thyroid, esophageal and tracheal tissues[71, 
72]. KLK5 takes part in the skin desquamation proteolytic cascade in the stratum corneum, along 
with KLK7[57, 68]. It also has a role in seminal plasma liquefaction[57]. 
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KLK6 
The highest expression of KLK6 is found in CNS, breast, renal and uterine tissue; it has also been 
found in salivary glands, the spleen, heart, thymus, prostate, liver, thyroid, placenta, trachea and 
testis[71, 73]. KLK6 is secreted by oligodendrocytes and plays a primary role in remyelination 
and in maintaining a normal myelinated state[74]. 
KLK7 
The highest expression of KLK7 is found in skin, CNS, renal and breast tissues; it has also been 
found in salivary glands, thymus, uterus, thyroid, placenta, trachea, testis and ovaries[71]. Others 
have reported high expression in normal cervix, ovaries, testes, esophagus, stomach and low 
expression in normal colon[68]. KLK7 has shown strong staining patterns for NSGT[67]. KLK7 
has a significant role in skin desquamation, and demonstrates co-expression with other KLKs in 
this proteolytic function[57, 68]. KLK5 and KLK7 function to degrade corneodesmosomes, which 
interconnect the stratum corneum; this degradation is a pre-requisite for skin desquamation[68]. 
Furthermore, KLK7 is co-expressed with KLK14 for additional skin desquamation activity[55]. 
KLK8 
The highest expression of KLK8 is found in CNS, skin and ovarian tissues; it has also been found 
in esophagus, testis, tonsillar, renal, breast, and salivary gland tissue[54, 71]. KLK8 has been 
demonstrated in a number of bodily fluids: breast milk, amniotic fluid, seminal fluid, and 
serum[54]. 
KLK9 
The highest expression of KLK9 is found in the thymus, testis, CNS and trachea; is has also been 
found in breast, prostate, salivary glands, ovaries and skin[71]. 
KLK10 
The highest expression of KLK10 is found in breast, ovarian, testicular, and prostate tissues; it has 
also been found in the small intestine, lung, colon, pancreas, uterus, CNS, salivary glands and 
trachea[71]. KLK10 has demonstrated high expression in the islets of Langerhans in the pancreas, 
and may have a role in regulation of insulin, glucagons, somatostatin, and pancreatic 
polypeptide[55]. KLK10 also participates in the proteolytic process of skin desquamation, which 
may be mediated through the processing of desmoglein1 (DSG1)[55]. 
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KLK11 
The highest expression of KLK11 is found in brain, skin, salivary gland, stomach, uterus, lung, 
thymus, prostate, spleen, liver, small intestine, and trachea; it has also been found in the heart, fetal 
liver, breast, thyroid, and skeletal muscle[71]. 
KLK12 
The highest expression of KLK12 is found in salivary glands, stomach, uterus, trachea, prostate, 
thymus, lung, colon, brain, breast, and thyroid; it has also been found in testis, pancreas, small 
intestine, and spinal cord[71]. 
KLK13 
The highest expression of KLK13 is found in breast, prostate, salivary glands, and testis; it has 
also been found in the lung, heart, adrenal, colon, thyroid, and tracheal tissues[71]. Along with 
KLK10, KLK13 has demonstrated high expression in the islets of Langerhans in the pancreas, and 
may have a role in regulation of insulin, glucagons, somatostatin, and pancreatic polypeptide[55].  
KLK14 
The highest expression of KLK14 is found in the CNS; it has also been found in breast, thyroid, 
uterus, thymus, colon, spleen, placenta, small intestine, kidney and bone marrow tissues[71]. 
Others have reported high expression in normal brain tissue, along with prostate, testis, and 
thymus, with low expression in normal colon tissues[68]. Moderate immunohistochemical staining 
with KLK14 has been seen in salivary gland tissue[75]. KLK14 is involved in skin desquamation, 
and as noted previously, demonstrates co-expression with KLK7 in this proteolytic activity[57]. 
Moreover, KLK14 is thought to contribute to the hemostasis of seminal plasma[68]. 
KLK15 
The highest expression of KLK15 is found in the thyroid, salivary glands, and prostate; it has also 
been found in adrenal, colon, testicular, and renal tissues[71].  
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Figure 1.2.2.3 KLK expression in human tissues. This figure was originally published in 
Endocrinology Reviews. Yousef GM, Diamandis EP. The new human tissue kallikrein gene family: 
structure, function, and association to disease. 2001;22(2): 184-204. The figure is being 
reproduced for educational purposes only and not for any commercial use. Figure is included in 
the M. Sc. Dissertation with attribution. 
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1.2.2.7 Kallikreins in pathologic states 
Dysregulation of KLK expression leads to various pathologic states and aberrant regulation 
of KLKs has been implicated in a variety of diseases. This includes hypertension, renal disease, 
skin disorders, inflammation, neurodegenerative disease, and cancer[57, 60]. As demonstrated 
previously, KLKs show co-expression in physiologic states, as such, when KLKs are dysregulated, 
the co-expressed KLKs are coordinated[55]. 
Specific kallikreins have been implicated in certain diseased states. The aberrant regulation 
of KLK1 is associated with skin abnormalities[50]. KLK7 dysregulation has been implicated in 
chronic itchy dermatitis, psoriasis, and atopic dermatitis[50]. KLK8 has notable upregulation in 
conditions with hyperkeratotic features, such as seborrheic keratosis, psoriasis vulgaris, lichen 
planus, and squamous cell carcinoma, as compared to normal skin tissue, where minimal KLK8 is 
localized[50]. Aberrant expression of KLK14 results in pathologic skin conditions like atopic 
dermatitis, acute eczematous atopic skin[68]. 
KLK6 has been suggested as a potential biomarker for Alzheimer’s disease, as decrease 
levels of KLK6 in CSF have been observed in Alzheimer’s patients, and therefore, it has been 
suggested as a risk factor for this disease[50, 60]. KLK8 has been noted to be upregulated in the 
hippocampus of patients with Alzheimer’s disease[50].  KLK10 upregulation, along with KLK7 
co-expression and upregulation, has been linked with Alzheimer’s disease[50, 55].  Additionally, 
KLK6 dysregulation has been implicated in Parkinson’s disease[50]. KLK6, KLK7, and KLK10 
expression has been demonstrably lower in patients with frontotemporal dementia[50]. 
Many KLKs demonstrate aberrant expression in malignant pathologic processes, and as 
such, this will be discussed in a separate section.  
1.2.2.8 Kallikreins and malignancy 
KLKs have been shown to be aberrantly regulated in almost all human solid tumours, and 
in particular, dysregulation of KLKs in steroid-dependent cancers (e.g. breast, prostate, ovarian) 
has been well documented[58, 76].  
KLKs 1,3,5-10, and 12-15 have demonstrated aberrant expression in breast cancer cells[50, 
58, 64]. KLK6 becomes downregulated in metastatic breast cancer cells, when compared to 
primary breast cancer cells and normal breast tissue[73]. KLK7 is downregulated in breast cancer 
tissue; however, contradictory reports are found in the literature[67, 68, 77]. KLK10 and 12 are 
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associated with breast cancer, and demonstrate downregulation[53, 55]. KLK13 is downregulated 
in a subset of breast carcinoma[53]. KLK14 is over expressed in breast cancer cells[68].  
KLKs 2-11, and 13-15 have been found aberrantly expressed in ovarian cancer cells[58, 
64]. For example, KLK4 is expressed in ovarian cancer, but it not seen in normal ovarian 
tissue[50]. KLK5 demonstrates higher expression in late stage serous ovarian carcinoma[73]. 
KLK6, 7, 8, 13 and 14 demonstrate over-expression in ovarian cancer[53, 67, 68, 76, 77].  
KLKs 2-6, 10,11, and 13-15 have demonstrated dysregulation in prostate cancer[58, 64]. 
In prostate cancer, serum levels of KLK3 may be dramatically increased; KLK3 expression is 
primarily confined to the glandular ducts and when glandular architecture is lost in malignancy, it 
is postulated KLK3 is released into the blood stream[56]. In the prostate tumour cells, KLK3 
expression is downregulated[64]. KLK7 is downregulated in prostate cancer cells[68, 77]. KLK14 
is expressed in prostate cancer to a similar degree that KLK2 and 3 are over-expressed[68, 75].  
In lung adenocarcinoma, KLK5, 7 and 8 antibody staining was positive in the nucleus of 
the tumour cells[67, 75]. KLK5 is relatively downregulated in testicular cancer, when compared 
to high levels of KLK5 expression in normal testis[53, 72]. KLK7 is upregulated in cervical, colon, 
intracranial, oral squamous cell and pancreatic cancer cells, and down regulated in melanoma and 
kidney cancer cells[67, 68, 77]. KLK10 is upregulated in colon cancer cells, with advanced 
colorectal tumours demonstrated high KLK10 expression[55, 63]. Dysregulation of KLK10 has 
been linked with testicular cancer, and along with co-expression of KLK6, skin carcinomas[55]. 
KLK14 has also been demonstrably upregulated in salivary gland malignancies[68].  
Aberrant KLK expression has been implicated in various malignant pathological processes, 
and various stages of cancer development[68]. KLKs have been postulated to maintain a dual role 
as both stimulatory and inhibitory factors that modulate tumour behaviour[67]. Furthermore, KLK 
dysregulation can promote carcinogenesis or inhibit cancer activities, and this may be tumour-site 
specific[55]. Experimental evidence has demonstrated that KLKs may influence malignant growth 
potential, angiogenesis, tumour invasion and metastasis via proteolytic cascades[55, 75]. 
Specifically, the proteolytic processing of growth factor-binding proteins, activation of growth 
factors and other proteases, releasing angiogenic or anti-angiogenic factors, and the degradation 
of ECM components may promote tumorgenesis[55, 75].  
Specific KLKs have been implicated in tumour progression. KLKs 1-4,6,7, 13 and 15 
function in ECM degradation, and angiogenesis, ultimately contributing to tumour invasion and 
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metastasis[64, 76]. More specifically, KLK7 is known to degrade ECM components in pancreatic 
cancer cells, thereby promoting metastasis; fibronectin is degraded, which leads to tumorgenesis 
and desmosomal proteins are degraded, decreasing cell adhesion and promoting tumour 
invasion[67, 68]. KLK7 role in tumour invasion and progression has been suggested, as in prostate 
cancer cells, the protease induces epithelial to mesenchymal transition[68]. KLKs 1-3 are involved 
in tumour growth regulation via their actions on insulin growth factors[64]. KLK14, which is 
produced by colon tumour cells, has been shown to activate proteinase-activating receptors 
(PARs), contributing to tumorgenesis[68]. Interestingly, KLK3, 6, and 13 also show anti-
angiogenic properties[64]. 
1.2.2.9 Kallikreins and salivary gland neoplasia 
 The association between kallikreins and salivary gland tissue has been well established. 
Multiple KLKs have been found in NSGT, including KLK1,2,9,10,13; moreover, most KLKs have 
been detected in salivary gland tissues by RT-PCR and other methodology[73, 76]. Some KLKs 
have demonstrated high expression in NSGT, which may indicate an active KLK proteolytic 
cascade in these tissues[67].  
 A summary of the findings to date on KLKs in salivary gland benign and malignant 
neoplasia will now be presented. KLK3 has been found via in-situ hybridization in NSGT; 
however, this finding was not corroborated by Darling et al., who concluded KLK3 was not 
expressed in salivary gland tumours[72].  KLK5 is not expressed in NSGT; scant positive IHC 
staining has been seen for PA, ACC, ANOS, MEC, but none was deemed significant[72]. KLK6 
is expressed in salivary gland tumours; however, it is downregulated as compared with NSGT and 
the IHC staining demonstrated in tumour cells is non-specific[73, 76]. KLK7 has been detected in 
NSGT, and has been associated with salivary gland neoplasms, including: PA, ACC, MEC[67]. 
Significantly higher staining with KLK7 antibody has been seen in PA and ACC, as compared 
with MEC, which demonstrated both ductal and non-ductal staining, but was akin to NSGT stain 
levels[67]. This finding suggests KLK7 may have a role in myoepithelial differentiation[67]. 
Moreover, the expression of KLK7 in both NSGT and tumour tissue is similar to KLK14, which 
suggests possible cascade effect leading to tumorgenesis[67]. Nuclear staining in salivary gland 
tumours has also been seen with KLK7 antibodies[67]. Interestingly, the level of KLK7 expression 
has not shown any association with tumour stage, grade, site of tumour, or patient 
demographics[67]. KLK8 has been detected in NSGT, and high levels of expression are seen in 
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most salivary gland tumours[54]. Darling et al. found KLK8 antibody staining was significantly 
higher in ductal cells of NSGT and significantly higher in salivary gland malignancies[54]. KLK10 
demonstrates strong expression in NSGT, and staining of malignancies with KLK10 antibody is 
not significantly different; however, PA demonstrates significantly lower expression than 
NSGT[55]. At the cellular stain level, KLK10 shows higher intensity staining in serous acinar 
cells, and equivalent mucous acinar and ductal cell staining, when compared to NSGT[55]. KLK13 
has been linked to NSGT; PA shows lower KLK13 staining comparatively, whereas PLGA, ACC, 
ANOS stains significantly higher for KLK13 than NSGT[76]. Furthermore, KLK13 staining has 
been documented as higher in MEC and ACI (acinic cell), yet it is not significant[76]. KLK14 
expression has been noted in NSGT, with over-expression noted in PA (statistically significant) 
and ACC, and decreased expression in MEC[75]. Furthermore, nuclear specific staining has been 
associated with KLK14 in salivary gland tumours[75]. Of interest, Darling et al. showed a 
correlation between KLK7, 10, and 14 expression in ACC[55]. 
 To the authors knowledge, KLK expression has only been studied in PLGA by Darling et 
al., who examined the expression of KLK13 in 13 samples of PLGA[76]. They found KLK13 
stained greater in malignant salivary gland tumours, than benign salivary gland tumours and 
normal salivary gland tissue[76]. 
1.2.2.10 Kallikreins as biomarkers  
 Biomarkers have been widely adopted in medicine for the detection and measuring of 
biologic or disease states[78]. Biomarkers objectively measure substances, structures or processes 
in the body that influence or predict the incidence of outcome or disease[78]. Biomarkers have the 
potential to be used clinically in the diagnosis, prognosis, and recurrence of disease, with the goal 
of reducing mortality[78]. Ideally, a tumour biomarker would have the following characteristics: 
(1) expression in the pre-malignant or early malignant stage of the disease, (2) expressed in all 
patients with the specific malignancy at detectable levels, (3) accessible and non-invasive, (4) the 
quantity of expression equating to tumour bulk, clinical behaviour, or disease progression, (5) 
demonstrates a relatively short-half live to yield changes when disease in remission and/or to 
monitor disease progression, (6) measurable with a standardized, reproducible, and valid objective 
and quantitative assay[79]. Ultimately, biomarkers which are used for diagnostic and prognostic 
purposes, as well as for drug targeted therapies, would ideally be both highly specific and 
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sensitive[80]. Biomarkers may be categorized into pharmacodynamic, prognostic, or 
predictive[80].  
 Kallikreins have emerged as powerful tumour markers[57]. The most well-known 
biomarker is KLK3, also known as prostate specific antigen (PSA), and it has been regarded as the 
most valuable biomarker in clinical practice for prostate cancer diagnosis and monitoring of high 
risk populations [49, 57, 60, 76]. A serum PSA test indicates a measurement of the “total” immune-
reactive concentration of PSA in serum or plasma[56]. Implemented since the late 1980s, the PSA 
test, along with improved prostate cancer treatments, has contributed to a decrease age-adjusted 
death rate from prostate cancer of 40% in the United States[56]. The PSA test was validated by 
two high-quality European randomized controlled trials in the 1990s, demonstrating significant 
reduction in mortality in prostate cancer by screening men 55-69 years every two to four years and 
men 50-64 every two years[56]. Controversy over the widespread use of PSA screening arose with 
the U.S. trial, “Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO)”, as it 
concluded there was no statistically significant different in prostate-specific mortality risk between 
those screened and those who were not[56].   
Much controversy continues to exist on routine PSA screening, and pros and cons for PSA 
testing have been put forth. The potential benefits from PSA testing may include detection of 
disease prior to metastatic spread, earlier detection leading to more treatable disease and overall 
mortality reduction from prostate cancer; other benefits include the potential to diagnose benign 
prostatic hyperplasia (BPH)[56, 81]. Limitations of PSA screening include its lack of specificity, 
as many biologic conditions can cause an increase in PSA levels, such as BPH, increased age, 
prostatitis, and transient increase of PSA with ejaculation[81]. Obese men often demonstrate lower 
PSA levels, and certain drugs may also affect PSA levels (e.g. 5-alpha-reductase inhibitors)[81]. 
The PSA assay is not diagnostic alone, and if malignancy is suspected, additional tests will be 
required (e.g. tissue biopsy); moreover, a single PSA test will not provide information on the 
aggressiveness of disease. Harmful outcomes from the use of PSA include detecting prostate 
cancer which would not have become clinically significant in the patient’s lifetime, and therefore 
put the patient through treatment they may not have required[81]. If the PSA is not elevated, this 
may provide false reassurance to the patient, as disease could still be present[81]. There is also 
potential for false-positives, leading to unnecessary biopsies with accompanying serious 
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complications, over diagnosis, unneeded treatment with potential harmful sequelae (e.g 
impotence), and considerable anxiety[56, 81].  
This significant argument both for and against the routine use of PSA testing continues to 
be controversial and in 2012, the United States Preventative Services Task Force recommended 
against PSA screening; however, the American Urological Association (AUA) and the American 
Cancer Society (ACS) continue to recommend PSA testing[82]. In an effort to increase the 
specificity of PSA testing, logistic regression models that use the ratio of KLK2 to free PSA and 
the ratio of free PSA to total PSA have been useful in differentiating between BPH and prostate 
cancer[83].  
Additional KLKs have been suggested as possible biomarkers in prostate cancer. KLK5 
and KLK11 have been shown to be favourable prognostic markers in prostate cancer; KLK15 has 
been noted as an unfavourable prognostic marker[50, 53].   
KLKs have also been put forth as potential biomarkers for a variety of other malignancies. 
In ovarian cancer, KLK4-7, 10, 11, and 15 have all shown to be markers of unfavourable 
prognosis[50, 53, 72, 75]. KLK4 has been determined to be an independent indicator of poor 
prognosis in grade 1 and 2 ovarian tumours[50].  KLK7 has contradictorily been noted as both a 
favourable and unfavourable marker of prognosis; Dorn et al. reported that patients with high 
expression of KLK7 had significantly two-fold lower risk of death, and that KLK7 was 
significantly associated with overall and disease free survival[77]. KLK8,9,13, and 14 have been 
linked as favourable prognostication factors in ovarian cancer[50, 53]. KLK8 and KLK13 are 
upregulated in ovarian tumours and it’s higher expression has been found to be favourable[76]. 
Devetzi et al. concluded that KLK5, 11 and 14 are markers for ovarian cancer diagnosis, KLK6,8 
and 10 are markers for ovarian cancer diagnosis, prognosis and monitoring of disease[68].  
In breast cancer, KLK5,7,10 and 14 have all shown to be markers of unfavourable 
prognosis[50, 53, 72]. KLK10 and 14, while noted as poor prognostic factors, have also been 
demonstrably downregulated[50]. KLK10 was also found to be a predictor of invasiveness in 
ductal breast carcinoma[53]. In contrast, while it is noted to be unfavourable above, KLK7 has 
also been reported as a favourable prognostic marker in breast cancer[67]. Additional favourable 
prognostic markers include: KLK15[50, 53].  
In colon cancer, KLK7, 10, and 14 have been shown as markers of unfavourable 
prognosis[55, 68]. Specifically, KLK7 has been implicated as an unfavourable marker for overall 
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survival in colorectal cancer[68]. KLK10 and KLK14 are upregulated in colon cancer cells, and 
high expression of these proteases is seen in advance colorectal tumours, with higher KLK10 and 
KLK14 expression associated with decreased disease-free survival and overall survival rates[55, 
63, 68]. Lastly, in pancreatic ductal adenocarcinoma, KLK6 and 10 are co-expression and noted 
to confer a poor prognosis[55]. 
KLKs may also prove useful as potential targets for therapy and monitoring disease 
progression. PSA is once again an example of this, as there has been significant work on PSA 
targeted drug therapy, and sequential PSA testing is considered valuable post prostate cancer 
treatment, as a rising level often indicates recurrence[81]. Furthermore, KLK4 has been shown to 
be a protein marker for resistance to paclitaxel therapy in the treatment of ovarian cancer[50]. In 
ovarian cancer, KLK7 may be useful in predicting surgical success outcomes, and may also have 
value in assessing response to chemotherapy and/or the overall and disease-free survival[77]. 
To date, no KLK has been used as a biomarker in salivary gland malignancies. However, 
as most KLKs have been detected in salivary glands, this lends them to being useful as biomarkers 
of salivary gland malignancy, with potential to aid in diagnosis, prognosis and monitoring of 
disease[73].  
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1.3 Hypothesis, Rationale and Aims 
1.3.1 Hypothesis 
In this study, we hypothesize that human tissue kallikreins (KLK) are aberrantly expressed 
in polymorphous low-grade adenocarcinoma (PLGA), as compared to normal salivary gland tissue 
(NSGT). We further hypothesized that KLK expression, whether increased or decreased, may be 
demonstrated specifically in tumour cells.   
 
1.3.2 Rationale 
The diagnosis of PLGA, the second most common malignant salivary gland tumour of the 
minor glands, can often be challenging. This may be attributed to its various histologic 
appearances, which overlap with other salivary gland neoplasia. It is well established that delayed 
diagnosis of malignancies results in poorer patient outcomes, as well as increases patient 
morbidity[1].  
KLKs have been recognized as valuable tumour biomarkers, as they demonstrate aberrant 
regulation in malignant processes[67]. The most well-known is KLK3, or prostate specific antigen, 
which has contributed advancements to the diagnosis and monitoring of prostate adenocarcinoma, 
while also generating a potential therapy target[49].  
KLKs have been extensively studied in many glandular tumours, including breast and 
prostate carcinoma. KLK expression has previously been shown in NSGT[73, 76]. Furthermore, 
aberrant regulation of KLKs has been linked to other salivary gland tumours. This suggests their 
potential use as biomarkers in salivary gland neoplasms[67]. KLK levels in PLGA may lend 
themselves as diagnostic markers and prognostic markers to better recognize PLGA and 
differentiate tumour clinical behaviour. Lastly, the detection of KLKs in serum or other bodily 
fluids may provide a rapid and minimally invasive means of diagnosis in PLGA.  
To date, examination of KLK expression in PLGA is limited to KLK13 only. To the authors 
knowledge, this study is the first to look at the expression of KLK1-15 in PLGA, both at the level 
of mRNA and protein.  
 
1.3.3 Aims 
1. To determine levels of KLK (KLKs1-15) mRNA in formalin fixed paraffin embedded 
PLGA tissue samples, using real time polymerase chain reaction. 
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2. To determine if KLK expression is tumour cell-specific, by analyzing 
immunohistochemical expression of specific KLKs (KLK 7, KLK8, KLK10, KLK11, and 
KLK14) in PLGA tissue samples. The staining scores of each PLGA sample will then be 
compared to specific KLK mRNA levels. 
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Chapter 2 
 
2.0 Experimental Materials and Methods 
2.1 Tissue Specimens 
2.1.1 Tumour Criteria  
Cases of polymorphous low-grade adenocarcinoma were retrieved from the archives 
between 1987-2013 at University Hospital, London Health Sciences Centre and the Division of 
Oral Pathology, Schulich School of Medicine & Dentistry, Western University. Original 
hematoxylin and eosin (H&E) stained slides were reviewed to confirm a diagnosis of PLGA, and 
to verify enough tumour tissue for experimental use. Blocks of formalin-fixed, paraffin-embedded 
(FFPE) PLGA tissue were obtained for suitable cases. Some samples required re-embedding in 
paraffin wax and repeat H&E stain to confirm enough tumour tissue for our studies. Cases that did 
not have an original slide or FFPE blocks were omitted. A total of 19 PLGA tumours were 
obtained. 
 
2.1.2 Patient data collection from PLGA samples 
Data was obtained from each PLGA case. This included patient demographics (age, 
gender), tumour clinical features and microscopic findings. Specific clinical features recorded 
were the tumour site and whether not the tumour was a recurrence. Histologic findings noted were 
morphology (e.g. trabecular, cribriform), perineural invasion, encapsulation, and degree of 
infiltration. Table 3.1.1 lists patient demographics, including sex, age, location of the tumour and 
year of biopsy for each PLGA sample.  
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Table 2.1.1: Patient Demographics for PLGA Samples 
Sample 
# 
Pt 
Age 
Sex Location Year 
of 
Bx 
1 
 
56 F Posterior 
palate 
1994 
2 51 F Soft palate 2009 
3 78 F L posterior 
hard palate 
2002 
4 77 M R buccal 
mucosa 
2001 
5 67 M Upper lip 
Mucosa 
2008 
6 50 F L hard 
palate 
2009 
7 59 M L soft 
palate 
2005 
8 76 M L upper 
lip 
2013 
9 63 F Hard and 
soft palate 
jxn 
2003 
10 49 F R buccal 
mucosa 
2009 
 
11 17 F mid hard 
palate/soft 
palate jxn 
2007 
12 65 F L hard 
palate 
2009 
13 83 M Sublingual 
gland 
2002 
14 76 M  Soft palate 2004 
15 38 F L buccal 
vestibule 
2007 
16 54 F R 
hard/soft 
palate jxn 
2010 
17 65 F R buccal 
mucosa 
1992 
18  F L buccal 
mucosa 
1989 
19 61 F R soft 
palate 
1991 
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Table 2.1.2: Patient Demographics for NSGT Samples. This table was originally produced in 
Expression of kallikrein-related peptidases (KLKs) in Adenoid Cystic Carcinoma. Kerr, Zachary 
R. Electronic Thesis and Dissertation Reporitory. Paper 4096. The table is being reproduced for 
educational purposes only and not for any commercial use. Figure is included in the M. Sc. 
dissertation with attribution. 
 
Sample 
# 
Pt 
Age 
Sex Location 
1 
 
75 F Left gingiva  
2 38 F Left lower lip 
mucosa 
3 53 F Lower lip 
4 20 M Right lower 
lip 
5 24 M Right buccal 
mucosa 
6 68 F Left lower lip 
7 24 F Floor of 
mouth 
8 20 F Lower lip 
9 47 F Lower lip 
10 42 F Right lower 
lip 
11 18 M Left lower lip 
12 68 M Uvula 
13 55 M Right lower 
lip 
14 33 F Lower lip 
15 58 F Left hard 
palate 
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2.1.3 Tissue sectioning 
The regions representative of PLGA tissue on the H&E stained slides were circled and 
matched to the same region on the FFPE tissue block. A scalpel was used to encircle the tumour 
tissue by scoring the paraffin. A microtome (Microm HM 325, GMI Inc., Ramsey, MN, USA, 
SKU# 8243 30 1006) was used to prepare 3x10µm tissue curls from each of the 19 PLGA PPFE 
tissue blocks. The tissue samples were not selected for tumour sample only; therefore, specimens 
consisted of tumour tissue and surrounding non-tumour tissues.  The specimens were then placed 
in 1.5mL collection tubes.   
2.1.4 Normal Tissues 
Previous work on characterizing KLK mRNA expression in NSGT has been completed in 
the Division of Oral Pathology, Schulich School of Medicine & Dentistry, Western University. 
Kerr et al.  used 15 samples of NGST, all from minor salivary gland tissue. Demographic 
information for the NSGT Specimens is listed in Table 3.1.2. The same experimental design to 
determine KLK expression in PLGA was used for the NSGT samples, and this is outlined below 
[84]. These results were used as comparison against PLGA tumour tissue results. 
 
2.2 RNA isolation from formalin-fixed, paraffin-embedded tissue 
2.2.1 Deparaffinization 
For each sample of PLGA tumour, one 3x10µm curl of FFPE tissue was placed in a 1.5 
mL reaction tube and 800µL of Xylene was added. The tube was vortexed and incubated for 5 
minutes. Subsequent centrifugation was completed for 2 minutes at maximum speed (12000-14000 
x g) and the supernatant was discarded via aspiration.  Deparaffinization steps were repeated. 
Following deparaffinization, 800µL of absolute ethanol was added and the pellet was dislodged. 
Samples were centrifuged at maximum speed and the supernatant was discarded. Next, 800µL of 
70% ethanol was added to the tube. Following another centrifugation, the samples were lysed using 
tissue lysis buffer (Roche Applied Science, Mannheim, Germany, Catalogue number: 04 823 125 
001). 
 
2.2.2 RNA Isolation Protocol 
High Pure FFPE RNA Micro Kit (Roche Applied Science) was used to isolate RNA from 
each of the samples. Following tissue digestion, proteinase K was added to the tubes and the 
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samples were incubated for 3 hours at 55°C. Next, 200µL of Binding Buffer and 200µL of ethanol 
(absolute) was added. Proteinase K is a broad-spectrum serine protease, which is added to digest 
protein and remove contamination from the preparation of nuclei acids; proteinase K rapidly 
inactivates nucleases which may otherwise degrade DNA or RNA during purification. Ultimately, 
this enzyme inactivates RNases and DNases improving the stability of these nucleic acids, and 
removes contaminates yielding pure DNA and RNA[85].  Following this step, the lysate was added 
into the upper reservoir of the RNA column tube. Genomic DNA was eliminated using DNase 
solution. All other steps were performed as suggested by the manufacturer. RNA isolated was 
stored at -80 °C until time of analysis.  
 
2.2.3 RNA Quantification and cDNA synthesis 
Isolated total RNA was quantified using Qubit Fluorometer (Invitrogen, Carlsbad, CA, 
Catalogue no Q32866). The Qubit Fluorometer is able to accurately detect RNA concentrations of 
10pg/uL to 1ug/L. A fluorescent dye binds specifically to RNA; initially these dyes have low 
fluorescent properties, but emit a higher signal once bound to RNA, which is quantifiable.  Based 
on the lowest RNA yield, minimum of 0.32ng of total RNA was selected for cDNA synthesis. The 
iScript cDNA synthesis kit (Bio-Rad Laboratories (Canada) Ltd. Mississauga, ON, Catalogue 
number: 1708890) was used to synthesis complementary DNA (cDNA) from previously isolated 
RNA.   
 
2.3 SYBR Green Real Time Polymerase Chain Reaction (PCR) 
The CFX Connect PCR Detection System (Bio-Rad Laboratories (Canada) Ltd, 
Mississauga, ON) was used to measure transcript levels. Source of primers is indicated in Table 
3.3.1. PCR reaction consisted of 10µL RT2 SYBR® Green qPCR Mastermix (Qiagen, Toronto, 
ON Catalogue No 330500), 2µL primers, 2µL cDNA, and 6uL H2O. The RT-qPCR cycle protocol 
was completed as follows: one cycle of 10 minutes at 95°C for activation of Taq DNA polymerase, 
40 cycles of 15s at 95°C and 40 cycles of 1minute at 60°C for DNA amplification. Melting curve 
analysis was included in all qPCR studies. 
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Table 2.3.1: Qiagen Catalogue numbers for primer assays used in Custom PCR Plate 
Primer Assay Catalogue Number 
KLK1 QT00020664 
KLK 2 QT00088466 
KLK3 QT00027713 
KLK4 QT00495159 
KLK5 QT00010437 
KLK6 QT00013972 
KLK7 QT00028343 
KLK8 QT00017689 
KLK9 QT00057190 
KLK10 QT00039816 
KLK11 QT00011011 
KLK12 QT00067977 
KLK13 QT00029876 
KLK14 QT00039928 
KLK15 QT00035735 
β-actin QT01680476 
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2.4 Data analysis for PCR 
Data was analyzed by ΔΔCT using CFX Manager. CT is defined as the threshold cycle, which 
occurs when the fluorescence level reaches a certain amount in the PCR experiment[86]. 
ΔΔCT is a method of relative quantification, and calculates relative gene expression in a 
target and reference samples in comparison to a data normalizing gene[86]. Data was 
normalized to β-actin and normal salivary gland tissue mRNA was used as the comparator for 
ΔΔCT. 
 
2.5 Statistical Analysis 
For each KLK, the mean of mRNA expression in tumour samples was calculated, as was 
the standard error of mean. Data was tested for normality and non-parametric statistical analysis 
was determined to be appropriate. Statistical testing was performed with Mann-Whitney U Test 
and significance was set at p<0.05.  
 
2.6 Assay Methods 
2.6.1 Immunohistochemistry sample selection 
Samples were selected for immunohistochemistry after analyzing KLK mRNA levels from 
PCR data. Samples exhibiting relatively lower or higher mRNA levels of specific KLK were 
included. Table 3.6.1 outlines the samples used for immunohistochemistry experiments. 
 
2.6.2 Immunohistochemistry 
For the immunohistochemistry experiments, a standard immunoperoxidase staining 
method was employed. An indirect technique was used to localize tissue expression of KLK 7, 8, 
10, 11, and 14 in PLGA tissue samples. Positive controls (Table 3.6.2.1) and negative controls (no 
primary antibody) were included for all staining experiments.  
 
2.6.3 Antibody Selection 
For our study, the primary antibodies were donated by Dr. E. P. Diamandis, Department of 
Laboratory Medicine and Pathobiology at the University of Toronto, Toronto, Ontario. These 
antibodies included rabbit polyclonal antibodies produced in mammalian stable cell lines, against 
KLKs (KLK 7,8,10,11,14).  The production of these KLK antibodies has been fully described by 
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Diamandis et al. (Reference: Diamandis EP, et al. Pathology and Genetics of human kallikrein 6 
(zyme/protease M/neurosin) and preliminary clinical applications. Clin Biochem. 2000;33:369-
75).  
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Table 2.6.1: IHC samples 
Specific KLK 
Antibody 
Sample # Sample # 
 LOW LEVEL HIGH LEVEL 
KLK7 6 16 
KLK8 6, 16 11 
KLK 10 11 6, 10 
KLK 11 6 11 
KLK 14 6 11 
 
Table 2.6.2.1: Positive Controls for Selected KLK Antibodies 
Kallikrein antibody Positive control 
KLK 7 Adenoid cystic carcinoma 
KLK 8 Skin 
KLK 10 Normal salivary gland  
KLK 11 Prostate 
KLK 14 Skin 
 
Table 2.6.2.2: Specific KLK antibody dilutions  
Kallikrein Antibody Antibody titre Incubation 
KLK 7 1:3200 Overnight at 4°C 
KLK 8 1:100 Overnight at 4°C 
KLK 10 1:1200 Overnight at 4°C 
KLK 11 1:2400 Overnight at 4°C 
KLK 14 1:3200 Overnight at 4°C 
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2.6.4 Paraffin Sections 
Formalin-fixed, paraffin-embedded PLGA tissue blocks were obtained. A microtome 
(Microm HM 325, GMI Inc., Ramsey, MN, USA, SKU# 8243 30 1006) was used to prepare 5µm 
thick serial sections, which were transferred to a water bath at 45°C, mounted on positively charged 
microscopic slides and oven-dried overnight via incubation at 37°C. The following solution 
immersions were completed to de-paraffinize and rehydrate the tissue sections: 3 changes of 
xylene for 5 minutes, 100% ethanol for 3 minutes, 95% ethanol for 3 minutes, 70% ethanol for 1 
minute, 100% distilled water for 3 minutes. Quenching was completed with 3% hydrogen peroxide 
in methanol for 5 minutes, followed by rinsing in 100% distilled water, and PBS.  
 
2.6.5 Staining procedure 
The prepared tissue sections for each PLGA sample were subjected to antigen retrieval. 
Slides were placed in citrate buffer (pH 6.0), at 125 °C in a de-cloaking chamber. The slides were 
rinsed in water and PBS for 5 minutes. We blocked the slides using 10% horse serum at room 
temperature for 30 minutes. After blocking, appropriately diluted primary antibodies for the KLK 
were added to the slides according to conditions outlined in Table 3.7.2.2. Detection was 
performed ImmPRESS ® Reagent Kit (Vector Laboratories, Burlingame, CA, Catalogue No: MP-
7401). The slides were then stained with 3,3’-diaminobenzidine tetrahydrochloride (DAB 
Peroxidase Substrate Kit, Vector Laboratories, Burlingame, CA, Catalogue No: SK-4100) for 10 
minutes at room temperature. Slides were then counterstained with hematoxylin, dehydrated, and 
mounted using Cytoseal® (VWR, Mississauga, Ontario, Catalogue No: 48212-154).  
 
2.7 Data collection and statistical analysis for immunohistochemistry 
2.7.1 Scoring Criteria  
The KLK staining of each PLGA sample was viewed under brightfield microscopy and 
assessed semi-quantitatively, using a well-documented method, as described by Allred et al.[76, 
87]. This was completed by an Oral Pathologist and the graduate student author. A proportion 
score and intensity score, displayed in Tables 3.7.1.1 and 3.7.1.2 respectively, was used to evaluate 
each stained tissue sample. The proportion score indicates the estimated fraction of positive 
staining tumour cell nuclei (0-5), while the intensity score evaluates the average staining intensity 
of tumour cell nuclei. An overall staining score (OSS) was then generated, ranging from 0-8, for 
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each sample. A negative score is represented as 0, and positive scores range from 2-8[87]. Figure 
2.7.1.1 demonstrates a pictorial interpretation of the Allred scoring system[88]. 
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Table 2.7.1.1: Proportion score for estimated fraction of immunoreactive tumour cells  
Score Proportion of cells stained 
0 0 
1 <1/100 
2 1/100-1/10 
3 1/10-1/3 
4 1/3-2/3 
5 >2/3 
 
 
 
Table 2.7.1.2: Intensity score for tumour cells 
Score Staining Intensity 
0 None 
1 Weak 
2 Intermediate 
3 Strong 
 
 
 
 
 
 
 
 
 
 
 
	 49	
Figure 2.7.1.1 Diagrammatic Representation of Interpretation of Allred Scores. This figure 
was originally published in Journal of Pakistan Medical Association. Qureshi, A. and Pervez, S. 
Allred scoring for ER reporting and its impact in clearly distinguishing ER negative from ER 
positive breast cancers. 60:350; 2010. The figure is being reproduced for educational purposes 
only and not for any commercial use. Figure is included in the M. Sc. Dissertation with attribution. 
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Chapter 3 
 
3.0 Results 
 
3.1 RNA isolation 
The RNA isolated from PLGA samples is shown in Table 4.1.1. In samples 14, 18, and 19, 
the RNA amount was not detectable. The average amount of RNA obtained from the remaining 
16 samples was 0.297 µg/mL. Equal amount of RNA was used to synthesize cDNA for qPCR 
studies. 
3.2 Expression of KLKs in cDNA of PLGA 
The expression of KLK mRNA in samples of PLGA was examined for KLK1-15. All 
samples of PLGA tissue demonstrated expression of at least four KLKs and as many as thirteen 
KLKs. The percentages of PLGA tissues exhibiting each KLK are listed in Table 4.2.1. KLK7 was 
the least likely to be expressed in the samples, detectable in just 18.8% cases. KLK6, 11, and 13 
were present in 25% cases. Whereas, KLK1 and 2 were most commonly expressed. 
 
3.3 Expression of KLKs in PLGA compared to normal salivary gland tissue (NSGT) 
The mean expression of each KLK was calculated for all PLGA samples. Figures 4.3.1-
4.3.15 demonstrate KLK mRNA expression in PLGA tissues compared to NSGT. The data was 
tested for normality and statistical significance was determined using Mann Whitney U Test. For 
each KLK, the mean mRNA expression obtained from biological replicates was found to be greater 
in the PLGA samples compared to NSGT. This was statistically significant for 1, 4, 10, 12, 15. 
The relative fold change of mRNA expression for each KLK in PLGA versus NSGT is 
demonstrated in Figure 4.3.16. to illustrate the overall profile.  
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Table 3.1.1 RNA quantification by Qubit Fluorometer for each PLGA tissue sample.  
 
Sample 
Number 
RNA  
µg/mL 
1 0.091 
2 0.121 
3 0.075 
4 0.072 
5 0.214 
6 0.898 
7 0.139 
8 0.065 
9 0.322 
10 0.244 
11 1.04 
12 0.238 
13 0.520 
14 too low 
15 0.120 
16 0.426 
17 0.163 
18 too low 
19 too low 
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Table 3.2.1 Percentages of PLGA cases with detectable KLK mRNA. These percentages are 
generated by the number of case samples (out of 16 total) which demonstrated mRNA for each 
KLK.  
 
KLK PLGA % 
KLK1 87.5 
KLK2 87.5 
KLK3 62.5 
KLK4 43.8 
KLK5 68.8 
KLK6 25 
KLK7 18.8 
KLK8 31.3 
KLK9 50 
KLK10 62.5 
KLK11 25 
KLK12 68.8 
KLK13 25 
KLK14 37.5 
KLK15 37.5 
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Figure 3.3.1: Mean value of KLK1 mRNA expression in PLGA vs NSGT. Statistical 
significance determined by Mann Whitney U Test (p<0.05) 
 
 
Figure 3.3.2: Mean value of KLK2 mRNA expression in PLGA vs NSGT. Statistical 
significance determined by Mann Whitney U Test (p<0.05) 
 
 
0
0.2
0.4
0.6
0.8
Normal PLGA
K
LK
1 
m
R
N
A
*
0
0.2
0.4
0.6
0.8
Normal PLGA
K
LK
2 
m
R
N
A
	 54	
Figure 3.3.3: Mean value of KLK3 mRNA expression in PLGA vs NSGT. Statistical 
significance determined by Mann Whitney U Test (p<0.05) 
 
 
Figure 3.3.4: Mean value of KLK4 mRNA expression in PLGA vs NSGT. Statistical 
significance determined by Mann Whitney U Test (p<0.05) 
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Figure 3.3.5: Mean value of KLK5 mRNA expression in PLGA vs NSGT. Statistical 
significance determined by Mann Whitney U Test (p<0.05) 
 
 
Figure 3.3.6: Mean value of KLK6 mRNA expression in PLGA vs NSGT. Statistical 
significance determined by Mann Whitney U Test (p<0.05) 
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Figure 3.3.7: Mean value of KLK7 mRNA expression in PLGA vs NSGT. Statistical 
significance determined by Mann Whitney U Test (p<0.05) 
 
 
 
Figure 3.3.8: Mean value of KLK8 mRNA expression in PLGA vs NSGT. Statistical 
significance determined by Mann Whitney U Test (p<0.05) 
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Figure 3.3.9: Mean value of KLK9 mRNA expression in PLGA vs NSGT. Statistical 
significance determined by Mann Whitney U Test (p<0.05) 
 
 
Figure 3.3.10: Mean value of KLK10 mRNA expression in PLGA vs NSGT. Statistical 
significance determined by Mann Whitney U Test (p<0.05) 
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Figure 3.3.11: Mean value of KLK11 mRNA expression in PLGA vs NSGT. Statistical 
significance determined by Mann Whitney U Test (p<0.05) 
 
 
 
Figure 3.3.12: Mean value of KLK12 mRNA expression in PLGA vs NSGT. Statistical 
significance determined by Mann Whitney U Test (p<0.05) 
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Figure 3.3.13: Mean value of KLK13 mRNA expression in PLGA vs NSGT. Statistical 
significance determined by Mann Whitney U Test (p<0.05) 
 
 
 
Figure 3.3.14: Mean value of KLK14 mRNA expression in PLGA vs NSGT. Statistical 
significance determined by Mann Whitney U Test (p<0.05) 
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Figure 3.3.15: Mean value of KLK15 mRNA expression in PLGA vs NSGT. Statistical 
significance determined by Mann Whitney U Test (p<0.05) 
 
 
 
Figure 3.3.16: Relative fold increase of mRNA levels of KLK1-15 in PLGA tissue as 
compared with normal salivary gland tissues. Statistical significance determined by Mann 
Whitney U Test (p<0.05; illustrated by asterisk). Standard error of mean (SEM) is demarcated 
by the error bars. 
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Table 3.3.1 Calculated p-values, as determined by Mann Whitney U Test, for the 
comparison of expression of KLK1-15 in PLGA tissues and NSGT.  
KLK Gene p-value 
KLK1 0.00672 
KLK2 0.82588 
KLK3 0.59612 
KLK4 0.03236 
KLK5 0.238 
KLK6 Sample number low 
KLK7  Sample number low 
KLK8 0.15854 
KLK9 0.71138 
KLK10 0.00804 
KLK11 Sample number low 
KLK12 0.0536 
KLK13 Sample number low 
KLK14 0.88076 
KLK15 0.00386 
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3.4 Immunohistochemical staining results 
Representative immunohistochemical staining images are shown in Figures 4.4.1-4.4.5 of 
PLGA tissue samples stained for specific KLKs. For each KLK antibody, at least one PLGA 
sample demonstrating relatively low mRNA expression and one PLGA sample demonstrating 
relatively high mRNA expression are presented. Negative controls for each PLGA sample were 
completed with addition of primary antibody and images and are displayed in Figure 4.4.6. 
Furthermore, positive control tissues were stained for their respective KLK antibody and are 
presented in Figure 4.4.7. ACC was used as a positive control for a KLK7, skin was used as a 
positive control for KLK8 and KLK14, NSGT was used as a positive control for KLK10, and 
prostate tissue was used as a positive control for KLK11.  
The IHC staining results are outlined in Table 4.4.1. Samples demonstrating relatively high 
KLK expression exhibited staining of all tumour cells (grade 5) and the intensity grade of the stains 
varied from 1-3. Samples demonstrating relative low KLK expression exhibited staining of most 
tumour cells (grades 4-5) and the intensity grade of the stains varied from <1-3. With respect to 
localization of a specific KLK, the samples with higher mRNA expression demonstrated 
equivalent or increased grade of immunohistochemical staining, as compared to samples with 
lower mRNA expression. Most of the KLK immunoreactivity in PLGA samples was primarily 
cytoplasmic, with some exceptions. Nuclear staining pattern was seen with KLK7 (samples 6&16), 
KLK11 (samples 6&11), and KLK14 (samples 6&11). KLK10 exhibited inflammatory cell 
staining in sample 10, and epithelial cell staining in sample 11.  All samples noted negative stromal 
staining.  
 
 
 
 
 
 
 
 
 
 
 
	 63	
Figure 3.4.1 Immunohistochemical localization of KLK7 in PLGA. Sample 6 (a) had relatively 
low KLK7 mRNA expression on PCR, while Sample 16 (b) had relatively high KLK7 mRNA 
expression on PCR. {images taken at 200x magnification; blue = hematoxylin nuclear stain; 
brown = diaminobenzidine/DAB chromogen}. 
 
	 							 	
(a)           (b) 
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Figure 3.4.2 Immunohistochemical localization of KLK8 in PLGA. Samples 6 and 16 (a)&(b) 
had relatively low KLK8 mRNA expression on PCR, while Sample 11 (c) had relatively high KLK8 
mRNA expression on PCR. {images taken at 200x magnification; blue = hematoxylin nuclear 
stain; brown = diaminobenzidine/DAB chromogen}. 
 
	 						 	
(a)        (b) 
 
 
(c) 
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Figure 3.4.3 Immunohistochemical localization of KLK10 in PLGA. Sample 11 (a) had 
relatively low KLK10 mRNA expression on PCR, while Samples 6 (b) and 10 (c) had relatively 
high KLK10 mRNA expression on PCR. {images taken at 200x magnification; blue = hematoxylin 
nuclear stain; brown = diaminobenzidine/DAB chromogen}. 
 
						 	
(a)            (b) 
	
(c) 
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Figure 3.4.4 Immunohistochemical localization of KLK11 in PLGA. Sample 6 (a) had 
relatively low KLK11 mRNA expression on PCR, while Sample 11 (b) had relatively high KLK11 
mRNA expression on PCR. {images taken at 200x magnification; blue = hematoxylin nuclear 
stain; brown = diaminobenzidine/DAB chromogen}. 
 
       
(a)          (b) 
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Figure 3.4.5 Immunohistochemical localization of KLK14 in PLGA. Sample 6 (a) had 
relatively low KLK14 mRNA expression on PCR, while Sample 11 (b) had relatively high KLK14 
mRNA expression on PCR. {images taken at 200x magnification; blue = hematoxylin nuclear 
stain; brown = diaminobenzidine/DAB chromogen}. 
 
         
(a)            (b) 
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Figure 3.4.6 Negative controls for KLK staining. Below (a)-(d) demonstrate IHC on Samples 6, 
10, 11, and 16 respectively, completed without KLK (primary) antibody {images taken at 200x 
magnification; blue = hematoxylin nuclear stain; brown = diaminobenzidine/DAB chromogen}. 
 
        
(a)              (b) 
 
          
(c)            (d)  
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Figure 3.4.7 Immunohistochemical localization of KLK in controls. Representative 
immunohistochemical stain images of tissues with known KLK expression are shown. ACC (a) was 
used as a KLK7 control, Skin (b)&(e) was used as a control for KLK8 and 14 respectively, NSGT 
(c) was used as a KLK10 control, and prostate (d) was used as a KLK11 control {images taken at 
200x magnification; blue = hematoxylin nuclear stain; brown = diaminobenzidine/DAB 
chromogen}. 
      
(a)          (b) 
 
       
(c)           (d) 
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(e)  
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Table 3.4.1 Immunohistochemistry stain results. IHC proportionality grade, intensity and 
overall score are recorded below, along with specific staining characteristics seen in each 
sample.   
 
Antibody Sample 
# 
Level 
of 
mRNA 
IHC 
Grade 
IHC 
Intensity 
IHC 
Score 
Stromal 
Stain 
OTHER 
KLK7 6 low 5 2 7 - Cytoplasmic and 
nuclear staining 
KLK7 16 high 5 2 7 - Cytoplasmic and 
nuclear staining 
KLK8 6 low 4 1 5 - Primarily 
cytoplasmic 
staining 
KLK8 16 low 4 1 5 - Primarily 
cytoplasmic 
staining 
KLK8 11 high 5 1 6 - All cytoplasmic 
staining 
KLK10 11 low 5 1 6 - Epithelial positive 
cells 
KLK10 6 high 5 1 6 - All cytoplasmic 
staining 
KLK10 10 high 5 1 6 - All cytoplasmic 
staining; 
inflammatory 
cells staining 
positively  
KLK11 6 low 5 2 7 - Primary 
cytoplasmic 
staining; many 
nuclei staining 
KLK11 11 high 5 3 8 - Primary 
cytoplasmic 
staining; some 
positive and 
negative nuclei 
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KLK14 6 low 5 3 8 - Primarily 
cytoplasmic 
staining; some 
nuclei staining 
KLK14 11 high 5 3 8 - Primarily 
cytoplasmic 
staining; much 
nuclear staining 
 
 
Table 3.5.1 Summary of PCR and IHC results 
 Total PLGA 
Samples 
Case 6 Case 10 Case 11 Case 16 
 average 
level of 
mRNA 
Median 
value of 
mRNA 
mRNA IHC 
score 
mRNA IHC 
score 
mRNA  IHC 
score 
mRNA IHC 
score 
KLK7 0.45908 0.37725 Low, 
0.0 
7     High, 
0.377251 
7 
KLK8 0.25982 0.09694 Low, 
0.0969368 
5   High, 
1.0  
7 Low, 
0.1049704 
5 
KLK10 0.27191 0.12312 High, 
0.225234 
6 High, 
0.138793 
6 Low, 
0.048942 
6   
KLK11 0.51035 0.44622 Low, 
0.0 
7   High, 
1.0 
8   
KLK14 0.18320 0.02862 Low, 
0.02862 
8   High, 
1.0 
8   
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3.5 PCR and IHC Correlation  
The results from PCR KLK mRNA quantification and IHC staining were compared and 
the findings are summarized in Table 4.5.1.  
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Chapter 4 
 
4.0 Discussion 
 
4.1 Increased mRNA levels of KLKs in PLGA 
 Our study confirms the hypothesis that KLKs are aberrantly expression in PLGA. Through 
qPCR, we demonstrated that KLK mRNA levels are increased in PLGA compared to normal 
salivary gland tissues. This upregulation was statistically significant for KLK1, KLK4, KLK10, 
KLK12, and KLK15, as determined by Mann Whitney U Test (p<0.05). We also noted greater 
variability in mRNA levels of KLK6, KLK7, KLK11 and KLK13; indicative of lower percentages 
of samples expressing these KLKs: 25%, 18.8%, 25% and 25%, respectively. 
 
4.2 IHC demonstrates PLGA tumour cell-specific staining pattern 
To address whether KLK upregulation in PLGA samples was specific to the tumour cells, 
we performed immunohistochemistry.  For these studies, we randomly selected patient samples 
showing relatively high and low mRNA levels (arbitrary) for KLK for which antibodies were 
available. These KLKs included KLK7, KLK8, KLK10, KLK11, and KLK14. PLGA samples 
were stained and evaluated, using a well-documented system[76]. Proportion scores for each 
PLGA case stained with KLK antibody noted most tumour cells were staining positive (proportion 
score 5), save for two samples with KLK8 demonstrating scores of 4, indicating slightly less 
percentage of tumour cells which were immunoreactive. Intensity scores varied between cases. 
These results confirmed our hypothesis that tumour cells are the primary source of KLK mRNA.  
 
4.3 KLK mRNA profile of PLGA vs ACC 
Our laboratory has recently profiled ACC samples for KLK mRNA levels, providing us 
with a unique opportunity to compare the profile to PLGA [84]. ACC samples exhibited 
significantly lower levels of KLK1, KLK8, KLK11 and KLK14 compared to NSGT; the remaining 
KLKs were expressed at levels comparable to that of NSGT[84]. In the present study, KLK1, 
KLK4, KLK10, KLK12, and KLK15 were found to be significantly upregulated when compared 
to NSGT. These differences, particularly KLK1, may be useful in distinguishing PLGA from ACC, 
which can pose a diagnostic challenge due to their histomorphologic resemblance[14, 34].  
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Microscopically, both PLGA and ACC exhibit diffusely invasive borders, solid and 
cribriform growth patterns, and perineural invasion[35]. ACC is more common in major salivary 
glands, which is a distinguishing feature versus PLGA’s predilection for the minor salivary glands; 
smaller cell size with less cytoplasm and nuclear features may also differentiate ACC from 
PLGA[6, 9]. Due to their prognostic distinctions, ACC having a worse prognosis and more 
aggressive clinical course as compared to PLGA, misdiagnosis between these two tumours would 
be an erroneous pitfall[9].  KLK1 mRNA was present in 73% of ACC samples studied by Kerr et 
al., and in the present study, KLK1 mRNA was expressed in 87.5% of PLGA samples[84]. Given 
KLK1 was found to be significantly downregulated in ACC and significantly upregulated in 
PLGA, this difference may lend itself to establishing a diagnostic panel, differentiating these two 
salivary gland tumours.  
 
4.4 Analysis of IHC staining of KLKs in PLGA 
 Overall, each sample with a relatively higher expression of KLK mRNA stained 
equivalently or with a higher IHC score than the samples which had relatively lower KLK mRNA 
expression. For KLK7, sample 6 demonstrated no mRNA expression, and sample 16 showed 
relatively higher expression; however, both samples had equivalent IHC scores of 7. Similarly, for 
KLK10, sample 11 had relatively low mRNA expression in comparison to samples 6 and 10, yet 
the IHC score for all samples was 6. Furthermore, for KLK14, sample 6 had relatively low mRNA 
expression in comparison to sample 11; IHC scores for both samples were 8. A small increase was 
seen between samples for KLK11, with sample 6 demonstrating undetectable mRNA and an IHC 
score of 7, while sample 11 having relatively higher mRNA expression and an IHC score of 8. The 
most significant difference was seen with KLK8; sample 6 and sample 16 demonstrated relatively 
lower mRNA levels and had IHC scores of 5, while sample 11 had relatively high mRNA and an 
IHC score of 7. 
 Additional IHC staining results note that all samples demonstrated negative stromal 
staining. Most samples exhibited primarily cytoplasmic staining for KLK. Nuclear staining was 
seen for KLK7, KLK11 and KLK14. KLK10 demonstrated positive epithelial cell staining in 
sample 11, while inflammatory cells stained positive for KLK10 in sample 10. Nuclear staining 
with KLK7 in PLGA mirrors previous IHC results from PA, ACC, and MEC samples from our 
laboratory[67]. 
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 It is currently not clear as to why a sample with no demonstrable KLK mRNA on PCR 
would stain positively for KLK protein. There could be a number of factors involved. For example, 
immunoreactivity may represent sequestered protein rather than tumour-expressed protein. The 
reactivity may also suggest high endogenous peroxidase activity in the PLGA specimens; 
although, this may usually be confined to red and white blood cells[89]. Furthermore, this could 
be attributed to nonspecific staining of the PLGA tissue samples. Tissue handling, including 
fixative exposure and tissue desiccation may also contribute to non-specific staining.  
 The no to minimal differences in IHC scores between samples with low and high mRNA 
expression may be explained by a number of postulations. PCR determines the amount of mRNA, 
which may not perfectly correlate with the amount of protein assessed by IHC. Tumour cells may 
be increasing mRNA stability which may lead to higher levels of transcripts. It is also possible that 
since KLKs are secreted proteases, the rate of secretion may outpace translation. However, these 
interesting avenues need further testing.  
 
4.5 IHC staining of KLKs in salivary gland neoplasia 
 Darling et al., and Hashem et al. have completed significant work on KLK IHC staining 
profiles of salivary gland neoplasia, as well as NSGT, including most of the KLKs used in this 
study (KLK7, 8, 10 and 14). Hashem et al. noted KLK7 was significantly overexpressed in PA 
and ACC (OSS 7.0 and 7.5 respectively), when compared to NSGT (OSS 6.5)[67]. Furthermore, 
MEC (OSS 6.33) was not significantly different from NSGT. The PLGA cases in this study, 
whether they had relatively low or higher mRNA expression, both had OSS of 7.0, which we can 
extrapolate as significantly increased as compared to NSGT. In previous work by Darling et al., 
KLK8 was shown to be expressed in NSGT (OSS 7.0), and to demonstrate equal or increased OSS 
in most malignancies: ACC (OSS 7.0+/-1.4), PLGA (OSS 6.9+/-0.5), ACI (OSS 7.0+/-0.8), ANOS 
(OSS 7.6+/-0.7), and MEC (OSS 7.5+/-0.5)[54]. In the present study, OSS in relative low-
expressing KLK8 mRNA samples was 5, and in relatively higher expressing KLK8 mRNA 
samples was 7, which is reasonably consistent with previous work. Darling et al. also described 
KLK10 as found in NSGT (OSS 6.0), and no significant differences in KLK10 expression were 
seen in malignancy: ACC (OSS 5.8), MEC (OSS 6.3)[55]. PLGA was not investigated in Darling 
et al.’s study; however, in the present study, the OSS for KLK10 of our PLGA samples were 
consistent with the other salivary gland malignancies studied (OSS 6 for all three cases). Hashem 
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et al. noted KLK14 was present in NSGT (OSS 6.5), and that, while KLK14 was upregulated in 
PA (OSS 7.25), there was no significant differences seen in salivary gland malignancies: MEC 
(OSS 6.14), ACC (OSS 6.8)[55, 75]. KLK14 stains in our PLGA samples demonstrated OSS of 8, 
despite differences in mRNA levels. Taken together, KLK14 may be recognized as over-expressed 
in PLGA. Darling et al. noted KLK7, 10 and 14 appeared to be correlated in their expression in 
ACC, all demonstrating no significant difference from NSGT. This same correlation does not seem 
evident in our staining of PLGA; KLK7 and 14 show similar IHC profiles, but KLK10 shows 
lower staining scores.  
 Additional IHC include nuclear staining seen with KLK7, KLK11 and KLK14. This could 
suggest a role for these specific KLKs in transcription. Moreover, we could extrapolate that in 
PLGA tumours, specific KLKs are active at the nuclear level to aberrantly regulate transcription, 
leading to tumour pathogenic behaviour. Inflammatory cell staining was observed with KLK10, 
which could demonstrate its involvement with an inflammatory process, contributing to malignant 
features in the PLGA tumour. 
In our experiment, we did not compare NSGT and PLGA staining, as we were interested 
in correlated data from PCR (mRNA expression levels) with IHC, look to elucidate tumour specific 
staining. However, by review previous works that have used the same IHC protocol and staining 
scoring systems, this present study has added value to further characterizing KLK IHC staining 
profiles in salivary gland neoplasia. 
 
4.6 Study Limitations 
 A limitation to this experimental design is that we are unable to detect whether the KLK 
protein is indeed active, we are only able to localize the protein. It is well established that KLKs 
go through an extensive processing in order to be activated; this occurs through the “KLK 
Activome”[60]. KLK genes are transcribed into a pre-pro-enzyme, which goes on to be 
proteolytically processed into an inactive pro-KLK, which become secreted by cleaving their 
amino terminal signal peptide[57]. Lastly, the pro-KLK is activated into a mature peptidase 
extracellularly, by the cleavage of the amino terminal propeptide[51, 60]. This cleavage may be 
done by the KLK itself, a different KLK, or a different protease[57, 63]. To determine the amount 
of active KLK peptidases, one may consider measuring for the peptidase that leads to the final 
activation cleavage process.  
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 Another limitation to the study design was the decision to utilize the entire tissue 3x10µm 
tissue curls from the PLGA tissue samples, rather than selecting out for tumour tissue only. 
Therefore, in addition to tumour cells, stromal cells and normal salivary gland tissue were 
undeniably used in the experimentations, and this may have introduced a source of variability into 
the results.    
An additional limitation to the experimental design was the PLGA tissue samples coming 
from FFPE, stored in archives over a range of years (1987-2013). There has been suggestion that 
perhaps the length of storage of FFPE has effect on extracting macromolecules; however, in 2013, 
Kokkat, et al., demonstrated no significant difference between macromolecules extracted from 
FFPE blocks stored from a decade in comparison to current year blocks[90]. Some of our tissue 
samples were stored greater than 12 years, and perhaps this affected our results and could account 
for lack of specific KLK expression in our PLGA tissue samples. RNA does degrade over its 
storage time; however, partially degraded samples may still be used in downstream experiments, 
such as PCR[90]. Moreover, cross-linking as a result of the fixation process affects RNA 
extraction, but the molecules remain recoverable, in fragmented forms, which are useable for 
analysis, including determining mRNA expression[91]. It could be postulated that using fresh 
frozen tissue samples of PLGA tumour would yield more high quality nucleic acids, and this could 
have altered our results[91]. 
 A limitation to be addressed is that the RT-PCR experiments carried out on NSGT samples 
were completed by our group prior to completing RT-PCR on the PLGA samples used in our study. 
These two data sets were compared, despite being run at different times. A criticism of this would 
be that these data sets do not represent experiments run under the same conditions, as there can be 
day to day changes in fluorescence. As a means to combat this, good PCR practice is maintained 
with ensuring the housekeeping gene (β-actin) is 1-3 cycle thresholds of the normal. Repeating 
RT-PCR with both samples at the same interval may be of benefit and eliminate this weakness in 
our study.  
Another limitation to our study includes KLK antibody availability, as the only antibodies 
accessible for this experiment were KLK7, KLK8, KLK10, KLK11, and KLK14. Unfortunately, 
all of these selected KLKs, except KLK10, are represented in the PLGA samples at low 
percentages. For example, KLK7 was only expressed in 18.8% of PLGA samples. The exception 
was KLK10, shown to be expressed in 62.5% of PLGA samples.  
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Also, we chose to select representative PLGA samples for IHC, one with relatively higher 
mRNA expression for a specific KLK, and one for relatively lower mRNA expression for a specific 
KLK. This was done to address our aim of whether or not the increased expression of KLK mRNA 
was tumour specific. To further support our finding of IHC scores being equivalent or higher in 
those samples demonstrating relatively higher KLK mRNA as compared to those with relatively 
lower KLK mRNA expression, all of our PLGA tissue samples could have been stained with the 
available KLK antibodies.  
Lastly, a limitation to our study includes our inability to designate a single KLK as a 
biomarker for PLGA. As we note, KLKs are co-expressed in salivary gland neoplasia and we 
suspect KLKs to be acting in proteolytic cascades[75]. Therefore, what holds more promise is 
developing a pattern of KLK expression seen in PLGA, in comparison to different salivary gland 
tumours.  
 
4.7 Future directions 
4.7.1 PLGA and activation of a kallikrein protein cascade   
Gene expression of KLK1-15 was shown to be increased in PLGA tissue samples, relative 
to NSGT. This may indicate that all of the KLKs are involved in a complex proteolytic cascade in 
these salivary gland tumours, involving the transcription, translation and activation of each KLK. 
A method of confirming this increased transcription of the KLK chromosome locus in PLGA could 
involve examining the expression of the nearby genes for increased expression, mimicking that of 
KLKs, in PLGA tissue samples. On the centromeric end, the KLK chromosome locus 19q13.4 is 
flanked by testicular acid phosphatase (ACPT) and on the telomeric end, it is flanked by cancer-
associated gene (CAG) and Siglec-9[50]. We could measure transcript levels of ACPT, CAG and 
Siglec-9 in PLGA samples to test this notion. If and when it is established that there is an increase 
of both KLK1-15 transcription and their flanking genes ACPT, CAG, Siglec-9, further 
experiments could confirm the mechanisms of aberrant transcriptional activity of this region. This 
could be achieved by investigating epigenetic alterations in PLGA tissue samples. Genomic 
imprinting is an epigenetic process, which may include DNA methylation, histone modification, 
and/or chromatin folding[92]. Imprinted genes are thought to occur in clusters and may have 
associations with signalling pathways[93]. Genomic imprinting is known to contribute to various 
human diseases, including Prader-Willi and Angelman’s syndrome; it is also thought to be 
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associated with the development and progression of malignancies[94]. Specifically, DNA 
methylation is often associated with shutting a gene “off” and therefore, DNA hypomethylation 
leads to an aberrant increase in gene transcription, thought to be implicated in cancer development 
and progression[94]. Methylation assays could be utilized for the KLK chromosome locus 
19q13.4, and surrounding regions, in PLGA samples[92]. Results of DNA hypomethylation would 
indicate increased transcription of this locus in the development of PLGA tumours. Taken together, 
this increased expression of the KLK chromosome locus and surrounding genes, with epigenetic 
modifications to promote increased transcription, would support an active proteolytic cascade 
involving KLK1-15 in PLGA tumours.  
 
4.7.2 KLK upregulation and PRDK1 Hotspot Mutation in PLGA 
 PRKD1 is a gene that encodes a kinase, which has been implicated in a whole host of 
malignant processes, including: colorectal, breast, esophageal, laryngeal, and other cancers[26, 27, 
37]. In 2014, Weinreb et al. identified a PRDK1 hotspot mutation encoding p.Glu710Asp in 
PLGA[27]. Upon examining their tumour bank, they found this hotspot mutation was present in 
72.9% of cases[27]. Subsequently, the group concluded the PRDK1 mutation conferred a 
neoplastic advantage to the PLGA tumour cells, as there was a significant increase in metastatic-
free survival time in those with the mutation[27]. Given that PLGA is primarily indolent in nature, 
with a low incidence of distant metastasis, this may speak to the nature of the malignancy itself, 
rather than the hotspot mutation[11]. 
 It would be of value to examine the PLGA samples from our study for the PRDK1 hotspot 
mutation. This could be done by sequencing the PLGA samples, obtaining PRDK1 primers and 
completing PCR amplification to localize for the hotspot mutation.  Subsequently, this could then 
be compared to our KLK data, examining the level of mRNA expression of particular KLKs in 
each sample of PLGA having the hotspot mutation. Taken together, we would expect the samples 
that have significant increased expression of KLKs would also express the PRDK1 hotspot 
mutation.  
4.7.3 PLGA cell lines, KLK overexpression and knockdown 
 To better elucidate the function of KLKs in PLGA, it would be useful to study the effect 
of their activity or lack thereof on cancer cells. Previous studies have investigated the functional 
significance of select KLKs in cancer cell lines. In 1998, Goyal et al. transfected KLK10-negative 
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breast tumour cell lines with KLK10, and injected the cells in nude mice. They found that KLK10 
overexpression inhibited tumour growth suggesting a tumour suppression role of KLK10 in breast 
cancer[95]. More recently, Hu et al. performed a similar study in prostate cancer cells and also 
showed that KLK10 conferred a tumour suppression role [96]. 
To our knowledge, KLK expression, and the resultant behaviour, has not been examined 
in PLGA cell lines. When examining the consequences of PRDK1 mutation in cell behaviour, 
Weinreb et al. used non-malignant breast epithelial cell lines, as PLGA cell lines and non-
malignant minor salivary gland cell models were not available[27]. It would be ideal to have an 
established cell line from PLGA tumours; however, should this not be possible, there would be 
value in examining cell behaviour in non-malignant breast epithelial cell lines with modulated 
KLK expression. From the results of our study, it would be reasonable to examine either KLK1, 
4, 10, 12, or 15, as they were statistically upregulated, when compared to NSGT. An expression 
vector, for example coding for KLK1, or an empty vector could be transfected into cells, and 
subsequent in vitro cell migration and invasion assays and cell proliferation assays would then be 
performed to examine cell behaviour. Cells expressing KLK1 and KLK1 knockdown cells would 
be compared. In addition, cells with modulated KLK may be injected in nude mice and 
characteristics such as tumour growth, invasion and metastasis would be examined and compared. 
A functional study such as this design could provide useful information for tumour 
characterization, prognosis, clinical behaviour, and potentially lead to therapeutic targets[96]. 
 
4.7.4 Gender role in PLGA 
 PLGA more commonly occur in females, with a female-to-male ratio of 2.15:1[11, 19]. In 
our study, we presented 19 cases of PLGA, 13 of which were found in women, yielding an above 
average percentage of female patients. Given our results of increased expression of KLKs in 
PLGA, it is interesting to postulate why this gender over-representation may be and if this 
contributes to our overall results. It seems unclear as to why women are more likely than men to 
get PLGA; however, a reasonable thought could be the involvement of hormones in the regulation 
of tumour cells. Additionally, it would be useful to retrospectively examine the clinical features of 
each tumour sample. For example, determining if recurrences were seen more with female or male 
patients, or if clinical behaviour seemed to be gender specific. Unfortunately, with such a small 
sample size of 19, clinical significance would not be obtainable. Perhaps a multi-centre 
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retrospective analysis of patients with PLGA and the role of gender on tumour characteristics 
would be a useful task. 
  
4.7.5 KLK as biomarkers in PLGA 
 We note a limitation to our study was the inability to demonstrate a single KLK as a 
biomarker for PLGA; however, we have added to the KLK expression profile of PLGA, with hopes 
of further developing a recognizable KLK pattern in PLGA, when compared to other salivary gland 
neoplasia. A way to add information to KLK pattern in PLGA would be to examine released KLK 
in bodily secretions (e.g. saliva) in patients with known PLGA. FFPE tissue from the patient’s 
tumour would be used to examine KLK mRNA expression; however, this would then be compared 
released KLK protein in saliva, as determined by ELISA, to note any significant differences. As 
described in previous sections, biomarkers have been categorized as pharmacodynamics, 
prognostic, and predictive. While it would be an aim of future directions to develop an efficacious 
biomarker for PLGA which is diagnostic, it would also be valuable to have a prognostic biomarker, 
which could indicate the likely clinical course of disease the patient would endure if not treated, 
and/or the likely outcome of disease apart from treatment selection. A biomarker for PLGA would 
be unlikely to be pharmacodynamic and/or predictive, given the use of drug therapy has no 
demonstrable benefit at present. Again, we anticipate that multiple KLKs are involved in 
functional protein cascades and this additional experimentation would aid in further developing 
the KLK profile in salivary gland pathology. 
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Chapter 5 
5.0 Conclusion 
 This study examined the expression of human tissue kallikreins in PLGA. Quantification 
of KLK1-15 mRNA in this tumour has not been reported to date. Through RT-qPCR, we 
demonstrated that KLK1, KLK4, KLK10, KLK12, and KLK15 expression is upregulated in 
PLGA. The average levels of KLK1, KLK4, KLK10, KLK12, and KLK15 mRNA expressed in 
PLGA tissue samples were increased relative to NSGT. Immunohistochemistry was carried out on 
PLGA samples showing relatively lower or higher mRNA KLK expression, and showed tumour 
cell-specific immunoreactivity.  
 In conclusion, we believe KLK upregulation in PLGA indicates the involvement of a 
complex proteolytic cascade, and may involve KLK 1, KLK4, KLK10, KLK12, and KLK15. We 
suspect this upregulation of KLK activity may be involved in regulating malignant processes in 
PLGA, and thus implicated in determining its clinical characteristics, including indolent behaviour 
and infrequent metastatic spread. Furthermore, the results of this study significantly add to the 
KLK profile of salivary gland neoplasia, at the mRNA and protein level. Importantly, when 
combining the resultant KLK profile in PLGA with the recently elucidated KLK profile in ACC, 
the resultant differences may render a diagnostic panel useful in differentiating between the 
malignancies. 
  
 
 
 
 
 
 
 
 
 
 
 
 
	 84	
References: 
1.	 Miloro	M,	Ghali	G,	Larsen	PE,	Waite	PD:	Peterson's	Principles	of	Oral	and	Maxillofacial	
Surgery,	3rd	Edition.	(ed.	3rd).	People's	Medical	Publishing	House	USA,	2012	
2.	 Neville	B,	Damm	D,	Allen	C,	Bouquot	J:	Oral	and	Maxillofacial	Pathology,	3rd	Edition.	(ed.	
3).	W.B.	Saunders	Company,	2008	
3.	 Barnes	L:	Chapter	5:	Tumors	of	the	salivary	glands.	In	Eveson	J,	Auclair	P,	Gnepp	D,	El-
Naggar	A	(eds),	(ed.,	International	Agency	for	Research	on	Cancer,	World	Health	Orgaizatio,	2005,	
p	210	
4.	 Tian	Z,	Li	L,	Wang	L,	Hu	Y,	Li	J:	Salivary	gland	neoplasms	in	oral	and	maxillofacial	regions:	
a	23-year	retrospective	study	of	6982	cases	in	an	eastern	Chinese	population.	Int	J	Oral	Maxillofac	
Surg	39:235,	2010	
5.	 Bagheri	S,	Bell	RB,	Khan	HA:	Current	Therapy	in	Oral	and	Maxillofacial	Surgery.	Saunders,	
Elsevier	Inc,	2012	
6.	 Castle	JT,	Thompson	LD,	Frommelt	RA,	Wenig	BM,	Kessler	HP:	Polymorphous	low	grade	
adenocarcinoma:	a	clinicopathologic	study	of	164	cases.	Cancer	86:207,	1999	
7.	 Schwarz	S,	Müller	M,	Ettl	T,	Stockmann	P,	Zenk	J,	Agaimy	A:	Morphological	heterogeneity	
of	oral	salivary	gland	carcinomas:	a	clinicopathologic	study	of	41	cases	with	long	term	follow-up	
emphasizing	the	overlapping	spectrum	of	adenoid	cystic	carcinoma	and	polymorphous	low-grade	
adenocarcinoma.	Int	J	Clin	Exp	Pathol	4:336,	2011	
8.	 Potluri	A,	Prasad	J,	Levine	S,	Bastaki	J:	Polymorphous	low-grade	adenocarcinoma:	a	case	
report.	Dentomaxillofac	Radiol	42:14804843,	2013	
9.	 Darling	MR,	 Schneider	 JW,	Phillips	VM:	Polymorphous	 low-grade	adenocarcinoma	and	
adenoid	cystic	carcinoma:	a	review	and	comparison	of	immunohistochemical	markers.	Oral	Oncol	
38:641,	2002	
10.	 Kimple	AJ,	Austin	GK,	Shah	RN,	Welch	CM,	Funkhouser	WK,	Zanation	AM,	Shockley	WW:	
Polymorphous	 low-grade	 adenocarcinoma:	 a	 case	 series	 and	 determination	 of	 recurrence.	
Laryngoscope	124:2714,	2014	
11.	 Patel	TD,	Vazquez	A,	Marchiano	E,	Park	RC,	Baredes	S,	Eloy	JA:	Polymorphous	low-grade	
adenocarcinoma	of	 the	head	and	neck:	A	population-based	study	of	460	cases.	Laryngoscope	
125:1644,	2015	
12.	 Takhar	 AS,	 Simmons	 A,	 Ffolkes	 L,	 Hyde	 N:	 Not	 just	 another	 paediatric	 neck	 lump:	
metastatic	cribriform	adenocarcinoma	of	the	palate	in	an	adolescent.	J	Laryngol	Otol	129:194,	
2015	
13.	 Fonseca	FP,	Brierley	D,	Wright	JM,	Santos-Silva	AR,	Almeida	OP,	Rocha	AC,	Van	Heerden	
WF,	 Hunter	 KD:	 Polymorphous	 low-grade	 adenocarcinoma	 of	 the	 upper	 lip:	 11	 cases	 of	 an	
uncommon	diagnosis.	Oral	Surg	Oral	Med	Oral	Pathol	Oral	Radiol	119:566,	2015	
14.	 Rooper	L,	Sharma	R,	Bishop	JA:	Polymorphous	low	grade	adenocarcinoma	has	a	consistent	
p63+/p40-	 immunophenotype	 that	 helps	 distinguish	 it	 from	 adenoid	 cystic	 carcinoma	 and	
cellular	pleomorphic	adenoma.	Head	Neck	Pathol	9:79,	2015	
15.	 Olusanya	 AA,	 Akadiri	 OA,	 Akinmoladun	 VI,	 Adeyemi	 BF:	 Polymorphous	 low	 grade	
adenocarcinoma:	literature	review	and	report	of	lower	lip	lesion	with	suspected	lung	metastasis.	
J	Maxillofac	Oral	Surg	10:60,	2011	
	 85	
16.	 de	Araujo	VC,	Passador-Santos	F,	Turssi	C,	Soares	AB,	de	Araujo	NS:	Polymorphous	low-
grade	adenocarcinoma:	an	analysis	of	epidemiological	studies	and	hints	for	pathologists.	Diagn	
Pathol	8:6,	2013	
17.	 Fife	 TA,	 Smith	 B,	 Sullivan	 CA,	 Browne	 JD,	 Waltonen	 JD:	 Polymorphous	 low-grade	
adenocarcinoma:	a	17	patient	case	series.	Am	J	Otolaryngol	34:445,	2013	
18.	 Wang	XD,	Meng	LJ,	Hou	TT,	Zheng	C,	Huang	SH:	Frequency	and	distribution	pattern	of	
minor	salivary	gland	tumors	in	a	northeastern	Chinese	population:	a	retrospective	study	of	485	
patients.	J	Oral	Maxillofac	Surg	73:81,	2015	
19.	 Abu	El-Naaj	I,	Leiser	Y,	Wolff	A,	Peled	M:	Polymorphous	low	grade	adenocarcinoma:	case	
series	and	review	of	surgical	management.	J	Oral	Maxillofac	Surg	69:1967,	2011	
20.	 Andreu-Barasoain	M,	Vicente-Martin	J,	Gomez	de	la	Fuente	E,	Salamanca-Santamaria	J,	
Pampin-Franco	A,	Lopez-Estebaranz	JL:	Polymorphous	low-grade	adenocarcinoma	in	the	upper	
lip:	a	well-described	but	infrequently	recognized	tumor.	(ed.	Dermatology	Online	Journal,	2013,		
21.	 Chi	AC,	Neville	BW:	Surface	Papillary	Epithelial	Hyperplasia	(Rough	Mucosa)	is	a	Helpful	
Clue	for	Identification	of	Polymorphous	Low-Grade	Adenocarcinoma.	Head	Neck	Pathol	9:244,	
2015	
22.	 Etıt	 D,	 Altinel	 D,	 Bayol	 Ü,	 Tan	 A,	 Türelık	 Ö,	 Çukurova	 I:	 Polymorphous	 low-grade	
adenocarcinoma	located	in	the	maxillary	sinus.	Turk	Patoloji	Derg	28:274,	2012	
23.	 Sun	G,	Yang	X,	Tang	E,	Wen	J,	Lu	M,	Hu	Q:	The	treatment	of	sublingual	gland	tumours.	Int	
J	Oral	Maxillofac	Surg	39:863,	2010	
24.	 Lee	 DH,	 Yoon	 TM,	 Lee	 JK,	 Lim	 SC:	 Polymorphous	 low-grade	 adenocarcinoma	 of	 the	
maxillary	sinus.	J	Craniofac	Surg	24:e213,	2013	
25.	 Jafarian	 AH,	 Khazaeni	 K,	 Rahpeyma	 A,	 Khajehahmadi	 S:	 Polymorphous	 low-grade	
adenocarcinoma	of	the	larynx:	a	rare	case	report.	Arch	Iran	Med	16:560,	2013	
26.	 Weinreb	I,	Zhang	L,	Tirunagari	LM,	Sung	YS,	Chen	CL,	Perez-Ordonez	B,	Clarke	BA,	Skalova	
A,	Chiosea	SI,	Seethala	RR,	Waggott	D,	Boutros	PC,	How	C,	Liu	FF,	Irish	JC,	Goldstein	DP,	Gilbert	
R,	Ud	Din	N,	Assaad	A,	Hornick	JL,	Thompson	LD,	Antonescu	CR:	Novel	PRKD	gene	rearrangements	
and	variant	fusions	in	cribriform	adenocarcinoma	of	salivary	gland	origin.	Genes	Chromosomes	
Cancer	53:845,	2014	
27.	 Weinreb	I,	Piscuoglio	S,	Martelotto	LG,	Waggott	D,	Ng	CK,	Perez-Ordonez	B,	Harding	NJ,	
Alfaro	J,	Chu	KC,	Viale	A,	Fusco	N,	da	Cruz	Paula	A,	Marchio	C,	Sakr	RA,	Lim	R,	Thompson	LD,	
Chiosea	SI,	Seethala	RR,	Skalova	A,	Stelow	EB,	Fonseca	I,	Assaad	A,	How	C,	Wang	J,	de	Borja	R,	
Chan-Seng-Yue	M,	Howlett	CJ,	Nichols	AC,	Wen	YH,	Katabi	N,	Buchner	N,	Mullen	L,	Kislinger	T,	
Wouters	BG,	Liu	FF,	Norton	L,	McPherson	JD,	Rubin	BP,	Clarke	BA,	Weigelt	B,	Boutros	PC,	Reis-
Filho	 JS:	 Hotspot	 activating	 PRKD1	 somatic	 mutations	 in	 polymorphous	 low-grade	
adenocarcinomas	of	the	salivary	glands.	Nat	Genet	46:1166,	2014	
28.	 PRKD1	mutations	characterize	salivary	gland	polymorphous	low-grade	adenocarcinoma.	
Cancer	Discov	4:1255,	2014	
29.	 Thennavan	 A,	 Rao	 L,	 Radhakrishnan	 R:	 Polymorphous	 low-grade	 adenocarcinoma	 of	
maxillary	alveolus	metastasising	to	the	abdomen:	the	role	of	immunomarkers	in	diagnosis.	BMJ	
Case	Rep	2013,	2013	
30.	 Verma	V,	Mendenhall	WM,	Werning	 JW:	Polymorphous	 low-grade	adenocarcinoma	of	
the	head	and	neck.	Am	J	Clin	Oncol	37:624,	2014	
	 86	
31.	 Pogodzinski	 MS,	 Sabri	 AN,	 Lewis	 JE,	 Olsen	 KD:	 Retrospective	 study	 and	 review	 of	
polymorphous	low-grade	adenocarcinoma.	Laryngoscope	116:2145,	2006	
32.	 Dultra	 FK,	Barros	AC,	 Schaer-Barbosa	H,	 Figueiredo	AL,	Gurgel	CA,	Ramos	EA,	da	 Silva	
Carvalho	AM,	dos	Santos	JN:	Immunohistochemical	assessment	of	CD1a-positive	Langerhans	cells	
and	their	relationship	with	E-cadherin	in	minor	salivary	gland	tumors.	J	Oral	Pathol	Med	41:47,	
2012	
33.	 Michal	 M,	 Kacerovska	 D,	 Kazakov	 DV:	 Cribriform	 adenocarcinoma	 of	 the	 tongue	 and	
minor	salivary	glands:	a	review.	Head	Neck	Pathol	7	Suppl	1:S3,	2013	
34.	 Persson	 F,	 Fehr	 A,	 Sundelin	 K,	 Schulte	 B,	 Löning	 T,	 Stenman	 G:	 Studies	 of	 genomic	
imbalances	and	the	MYB-NFIB	gene	fusion	in	polymorphous	low-grade	adenocarcinoma	of	the	
head	and	neck.	Int	J	Oncol	40:80,	2012	
35.	 Beltran	 D,	 Faquin	 WC,	 Gallagher	 G,	 August	 M:	 Selective	 immunohistochemical	
comparison	of	polymorphous	low-grade	adenocarcinoma	and	adenoid	cystic	carcinoma.	J	Oral	
Maxillofac	Surg	64:415,	2006	
36.	 Seethala	RR,	Johnson	JT,	Barnes	EL,	Myers	EN:	Polymorphous	low-grade	adenocarcinoma:	
the	University	of	Pittsburgh	experience.	Arch	Otolaryngol	Head	Neck	Surg	136:385,	2010	
37.	 Majewska	H,	Skálová	A,	Weinreb	I,	Stodulski	D,	Hyrcza	M,	Stankiewicz	C,	Biernat	W:	Giant	
cribriform	adenocarcinoma	of	 the	 tongue	 showing	PRKD3	 rearrangement.	 Pol	 J	 Pathol	 67:84,	
2016	
38.	 Gailey	MP,	Bayon	R,	Robinson	RA:	Cribriform	adenocarcinoma	of	minor	salivary	gland:	a	
report	of	two	cases	with	an	emphasis	on	cytology.	Diagn	Cytopathol	42:1085,	2014	
39.	 do	Prado	RF,	da	Silva	Machado	AL,	Colombo	CE,	Carvalho	YR:	Immunohistochemical	study	
of	the	expression	of	 fatty	acid	synthase	and	Ki-67	 in	salivary	gland	tumors.	 J	Oral	Pathol	Med	
40:467,	2011	
40.	 Soini	Y,	Kamel	D,	Nuorva	K,	Lane	DP,	Vähäkangas	K,	Pääkkö	P:	Low	p53	protein	expression	
in	 salivary	 gland	 tumours	 compared	 with	 lung	 carcinomas.	 Virchows	 Arch	 A	 Pathol	 Anat	
Histopathol	421:415,	1992	
41.	 Maletzki	 C,	 Bodammer	 P,	 Breitrück	 A,	 Kerkhoff	 C:	 S100	 proteins	 as	 diagnostic	 and	
prognostic	markers	in	colorectal	and	hepatocellular	carcinoma.	Hepat	Mon	12:e7240,	2012	
42.	 Patel	 KR,	 Solomon	 IH,	 El-Mofty	 SK,	 Lewis	 JS,	 Chernock	 RD:	 Mammaglobin	 and	 S-100	
immunoreactivity	 in	 salivary	 gland	 carcinomas	 other	 than	 mammary	 analogue	 secretory	
carcinoma.	Hum	Pathol	44:2501,	2013	
43.	 Wang	Z,	Spaulding	B,	Sienko	A,	Liang	Y,	Li	H,	Nielsen	G,	Yub	Gong	G,	Ro	JY,	Jim	Zhai	Q:	
Mammaglobin,	a	valuable	diagnostic	marker	for	metastatic	breast	carcinoma.	Int	J	Clin	Exp	Pathol	
2:384,	2009	
44.	 Treasure	J,	Lane	A,	Jones	DB,	Wright	DH:	CD43	expression	in	B	cell	lymphoma.	J	Clin	Pathol	
45:1018,	1992	
45.	 Fok	 TC,	 Lapointe	H,	 Tuck	 AB,	 Chambers	 AF,	 Jackson-Boeters	 L,	 Daley	 TD,	 Darling	MR:	
Expression	and	localization	of	osteopontin,	homing	cell	adhesion	molecule/CD44,	and	integrin	
v3	 in	pleomorphic	adenoma,	polymorphous	 low-grade	adenocarcinoma,	and	adenoid	cystic	
carcinoma.	Oral	Surg	Oral	Med	Oral	Pathol	Oral	Radiol	116:743,	2013	
46.	 Frohwitter	G,	Buerger	H,	VAN	Diest	PJ,	Korsching	E,	Kleinheinz	J,	Fillies	T:	Cytokeratin	and	
protein	expression	patterns	in	squamous	cell	carcinoma	of	the	oral	cavity	provide	evidence	for	
two	distinct	pathogenetic	pathways.	Oncol	Lett	12:107,	2016	
	 87	
47.	 de	 Araújo	 VC,	 de	 Sousa	 SO,	 Carvalho	 YR,	 de	 Araújo	 NS:	 Application	 of	
immunohistochemistry	to	the	diagnosis	of	salivary	gland	tumors.	Appl	 Immunohistochem	Mol	
Morphol	8:195,	2000	
48.	 Ghazy	SE,	Helmy	IM,	Baghdadi	HM:	Maspin	and	MCM2	immunoprofiling	in	salivary	gland	
carcinomas.	Diagn	Pathol	6:89,	2011	
49.	 Kontos	CK,	Scorilas	A:	Kallikrein-related	peptidases	(KLKs):	a	gene	family	of	novel	cancer	
biomarkers.	Clin	Chem	Lab	Med	50:1877,	2012	
50.	 Obiezu	CV,	Diamandis	 EP:	Human	 tissue	 kallikrein	 gene	 family:	 applications	 in	 cancer.	
Cancer	Lett	224:1,	2005	
51.	 Pampalakis	G,	Sotiropoulou	G:	Tissue	kallikrein	proteolytic	cascade	pathways	in	normal	
physiology	and	cancer.	Biochim	Biophys	Acta	1776:22,	2007	
52.	 Campbell	DJ:	The	kallikrein-kinin	system	in	humans.	Clin	Exp	Pharmacol	Physiol	28:1060,	
2001	
53.	 Diamandis	EP,	Yousef	GM:	Human	tissue	kallikreins:	a	family	of	new	cancer	biomarkers.	
Clin	Chem	48:1198,	2002	
54.	 Darling	 MR,	 Tsai	 S,	 Jackson-Boeters	 L,	 Daley	 TD,	 Diamandis	 EP:	 Human	 kallikrein	 8	
expression	in	salivary	gland	tumors.	Head	Neck	Pathol	2:169,	2008	
55.	 Darling	MR,	Hashem	NN,	Zhang	 I,	Mohamed	AB,	Fung	K,	Kwan	K,	Mara	TW,	Daley	TD,	
Diamandis	EP:	Kallikrein-related	peptidase	10	expression	in	salivary	gland	tissues	and	tumours.	
Int	J	Biol	Markers	27:e381,	2012	
56.	 Thorek	DL,	Evans	MJ,	Carlsson	SV,	Ulmert	D,	Lilja	H:	Prostate-specific	kallikrein-related	
peptidases	and	their	relation	to	prostate	cancer	biology	and	detection.	Established	relevance	and	
emerging	roles.	Thromb	Haemost	110:484,	2013	
57.	 Pavlopoulou	A,	Pampalakis	G,	Michalopoulos	 I,	Sotiropoulou	G:	Evolutionary	history	of	
tissue	kallikreins.	PLoS	One	5:e13781,	2010	
58.	 Kryza	 T,	 Silva	 ML,	 Loessner	 D,	 Heuzé-Vourc'h	 N,	 Clements	 JA:	 The	 kallikrein-related	
peptidase	 family:	 Dysregulation	 and	 functions	 during	 cancer	 progression.	 Biochimie	 122:283,	
2016	
59.	 Schmitt	M,	Renné	T,	Scorilas	A:	The	kallikreins:	old	proteases	with	new	clinical	potentials.	
Thromb	Haemost	110:396,	2013	
60.	 Sotiropoulou	G,	Pampalakis	G,	Diamandis	EP:	Functional	roles	of	human	kallikrein-related	
peptidases.	J	Biol	Chem	284:32989,	2009	
61.	 Lundwall	A,	Band	V,	Blaber	M,	Clements	JA,	Courty	Y,	Diamandis	EP,	Fritz	H,	Lilja	H,	Malm	
J,	Maltais	LJ,	Olsson	AY,	Petraki	C,	Scorilas	A,	Sotiropoulou	G,	Stenman	UH,	Stephan	C,	Talieri	M,	
Yousef	 GM:	 A	 comprehensive	 nomenclature	 for	 serine	 proteases	 with	 homology	 to	 tissue	
kallikreins.	Biol	Chem	387:637,	2006	
62.	 Kontos	CK,	Chantzis	D,	Papadopoulos	IN,	Scorilas	A:	Kallikrein-related	peptidase	4	(KLK4)	
mRNA	predicts	short-term	relapse	in	colorectal	adenocarcinoma	patients.	Cancer	Lett	330:106,	
2013	
63.	 Alexopoulou	DK,	 Papadopoulos	 IN,	 Scorilas	 A:	 Clinical	 significance	 of	 kallikrein-related	
peptidase	(KLK10)	mRNA	expression	in	colorectal	cancer.	Clin	Biochem	46:1453,	2013	
64.	 Borgoño	CA,	Diamandis	EP:	The	emerging	roles	of	human	tissue	kallikreins	in	cancer.	Nat	
Rev	Cancer	4:876,	2004	
	 88	
65.	 Prassas	I,	Eissa	A,	Poda	G,	Diamandis	EP:	Unleashing	the	therapeutic	potential	of	human	
kallikrein-related	serine	proteases.	Nat	Rev	Drug	Discov	14:183,	2015	
66.	 Lawrence	 MG,	 Lai	 J,	 Clements	 JA:	 Kallikreins	 on	 steroids:	 structure,	 function,	 and	
hormonal	regulation	of	prostate-specific	antigen	and	the	extended	kallikrein	locus.	Endocr	Rev	
31:407,	2010	
67.	 Hashem	 Nea:	 Kallikrein-related	 peptidase	 7	 in	 salivary	 gland	 tumours:	
Immunohistochemical	Expression	Profile.	(ed.	Canadian	Journal	of	Pathology,	2011,		
68.	 Devetzi	M,	Trangas	T,	 Scorilas	A,	Xynopoulos	D,	Talieri	M:	Parallel	overexpression	and	
clinical	significance	of	kallikrein-related	peptidases	7	and	14	(KLK7KLK14)	in	colon	cancer.	Thromb	
Haemost	109:716,	2013	
69.	 Borgoño	CA,	Michael	 IP,	Diamandis	EP:	Human	tissue	kallikreins:	physiologic	 roles	and	
applications	in	cancer.	Mol	Cancer	Res	2:257,	2004	
70.	 Yousef	GM:	microRNAs:	a	new	frontier	in	kallikrein	research.	Biol	Chem	389:689,	2008	
71.	 Yousef	 GM,	 Diamandis	 EP:	 The	 new	 human	 tissue	 kallikrein	 gene	 family:	 structure,	
function,	and	association	to	disease.	Endocr	Rev	22:184,	2001	
72.	 Darling	 MR,	 Tsai	 S,	 Jackson-Boeters	 L,	 Daley	 TD,	 Diamandis	 EP:	 Human	 kallikrein	 3	
(prostate	specific	antigen)	and	human	kallikrein	5	expression	in	salivary	gland	tumors.	Int	J	Biol	
Markers	21:201,	2006	
73.	 Darling	MR,	Jackson-Boeters	L,	Daley	TD,	Diamandis	EP:	Human	kallikrein	6	expression	in	
salivary	gland	tumors.	J	Histochem	Cytochem	54:337,	2006	
74.	 Sotiropoulou	 G,	 Pampalakis	 G:	 Targeting	 the	 kallikrein-related	 peptidases	 for	 drug	
development.	Trends	Pharmacol	Sci	33:623,	2012	
75.	 Hashem	NN,	Mara	TW,	Mohamed	M,	Zhang	I,	Fung	K,	Kwan	KF,	Daley	TD,	Diamandis	EP,	
Darling	MR:	Human	kallikrein	14	(KLK14)	expression	in	salivary	gland	tumors.	Int	J	Biol	Markers	
25:32,	2010	
76.	 Darling	MR,	Jackson-Boeters	L,	Daley	TD,	Diamandis	EP:	Human	kallikrein	13	expression	
in	salivary	gland	tumors.	Int	J	Biol	Markers	21:106,	2006	
77.	 Dorn	J,	Gkazepis	A,	Kotzsch	M,	Kremer	M,	Propping	C,	Mayer	K,	Mengele	K,	Diamandis	EP,	
Kiechle	 M,	 Magdolen	 V,	 Schmitt	 M:	 Clinical	 value	 of	 protein	 expression	 of	 kallikrein-related	
peptidase	7	(KLK7)	in	ovarian	cancer.	Biol	Chem	395:95,	2014	
78.	 Strimbu	K,	Tavel	JA:	What	are	biomarkers?	Curr	Opin	HIV	AIDS	5:463,	2010	
79.	 Bigbee	W	HR:	Characteristics	of	the	Ideal	Tumor	Marker.	In	Kufe	DW	PR,	Weichselbaum	
RR,	et	al.,	editors.	(ed)	Holland-Frei	Cancer	Medicine.	6th	edition.,	(ed.	Hamilton,	ON,	BC	Decker,	
2003,		
80.	 Drucker	E,	Krapfenbauer	K:	Pitfalls	and	limitations	in	translation	from	biomarker	discovery	
to	clinical	utility	in	predictive	and	personalised	medicine.	EPMA	J	4:7,	2013	
81.	 Kirby	R:	The	role	of	PSA	in	detection	and	management	of	prostate	cancer.	Practitioner	
260:17,	2016	
82.	 Carter	HB:	American	Urological	Association	(AUA)	guideline	on	prostate	cancer	detection:	
process	and	rationale.	BJU	Int	112:543,	2013	
83.	 Emami	 N,	 Diamandis	 EP:	 Utility	 of	 kallikrein-related	 peptidases	 (KLKs)	 as	 cancer	
biomarkers.	Clin	Chem	54:1600,	2008	
84.	 Kerr	Z:	Expression	of	kallikrein-related	peptidases	(KLKs)	in	Adenoid	Cystic	Carcinoma.	In	
Ontario	UoW	(ed)	(ed.,	2016,		
	 89	
85.	 Rezadoost	MH,	Kordrostami	M,	Kumleh	HH:	An	efficient	protocol	for	isolation	of	inhibitor-
free	nucleic	acids	even	from	recalcitrant	plants.	3	Biotech	6:61,	2016	
86.	 Rao	X,	Huang	X,	Zhou	Z,	 Lin	X:	An	 improvement	of	 the	2ˆ(-delta	delta	CT)	method	 for	
quantitative	real-time	polymerase	chain	reaction	data	analysis.	Biostat	Bioinforma	Biomath	3:71,	
2013	
87.	 Allred	DC,	Clark	GM,	Elledge	R,	Fuqua	SA,	Brown	RW,	Chamness	GC,	Osborne	CK,	McGuire	
WL:	Association	of	p53	protein	expression	with	tumor	cell	proliferation	rate	and	clinical	outcome	
in	node-negative	breast	cancer.	J	Natl	Cancer	Inst	85:200,	1993	
88.	 Qureshi	A,	Pervez	S:	Allred	scoring	for	ER	reporting	and	it's	impact	in	clearly	distinguishing	
ER	negative	from	ER	positive	breast	cancers.	J	Pak	Med	Assoc	60:350,	2010	
89.	 Bourne	 J:	 Handbook	 of	 Immunoperoxidase	 Staining	Methods.	 (ed.,	 Dako	 Corporation,	
1983,		
90.	 Kokkat	TJ,	Patel	MS,	McGarvey	D,	LiVolsi	VA,	Baloch	ZW:	Archived	formalin-fixed	paraffin-
embedded	(FFPE)	blocks:	A	valuable	underexploited	resource	for	extraction	of	DNA,	RNA,	and	
protein.	Biopreserv	Biobank	11:101,	2013	
91.	 Patel	PG,	Selvarajah	S,	Boursalie	S,	How	NE,	Ejdelman	J,	Guerard	KP,	Bartlett	JM,	Lapointe	
J,	Park	PC,	Okello	JB,	Berman	DM:	Preparation	of	Formalin-fixed	Paraffin-embedded	Tissue	Cores	
for	both	RNA	and	DNA	Extraction.	J	Vis	Exp,	2016	
92.	 Sant	KE,	Nahar	MS,	Dolinoy	DC:	DNA	methylation	screening	and	analysis.	Methods	Mol	
Biol	889:385,	2012	
93.	 Kim	J,	Bretz	CL,	Lee	S:	Epigenetic	instability	of	imprinted	genes	in	human	cancers.	Nucleic	
Acids	Res	43:10689,	2015	
94.	 Hsu	CM,	Lin	PM,	Lin	HC,	Lai	CC,	Yang	CH,	Lin	SF,	Yang	MY:	Altered	Expression	of	Imprinted	
Genes	in	Squamous	Cell	Carcinoma	of	the	Head	and	Neck.	Anticancer	Res	36:2251,	2016	
95.	 Goyal	 J,	 Smith	 KM,	 Cowan	 JM,	Wazer	 DE,	 Lee	 SW,	 Band	 V:	 The	 role	 for	 NES1	 serine	
protease	as	a	novel	tumor	suppressor.	Cancer	Res	58:4782,	1998	
96.	 Hu	J,	Lei	H,	Fei	X,	Liang	S,	Xu	H,	Qin	D,	Wang	Y,	Wu	Y,	Li	B:	NES1/KLK10	gene	represses	
proliferation,	 enhances	 apoptosis	 and	 down-regulates	 glucose	 metabolism	 of	 PC3	 prostate	
cancer	cells.	Sci	Rep	5:17426,	2015	
 
 1 
JACQUELINE MARIE COX, BSc DDS MD  
Oral and Maxillofacial Surgery Resident (PGY6), London Health Sciences Centre, 
London, Ontario 
 
EDUCATION: 
  
2012-present  Oral and Maxillofacial Surgery Residency 
   London Health Sciences Centre and  
   Schulich School of Medicine and Dentistry 
Western University, London, ON 
 
2012-2017  Masters of Science 
   Department of Pathology 
   Western University, London, ON 
 
2013-2017  Doctor of Medicine 
   Schulich School of Medicine and Dentistry 
Western University, London, ON 
 
2010-2011  Clinical Dental Fellowship 
   Schulich School of Medicine and Dentistry 
Western University, London, ON 
 
2006-2010  Doctor of Dental Surgery 
   Faculty of Dentistry 
   Dalhousie University, Halifax, Nova Scotia 
 
2002-2006  Bachelor of Science, Microbiology and Immunology 
   Dalhousie University, Halifax, Nova Scotia 
  
 
OTHER TRAINING AND SELF-LEARNING 
 
2016 OMFS Externship (September 26-30, 2016), University of 
Michigan Health System. Supervisor: Dr. Sean Edwards.  
 
2016 Trauma Elective (June 6 – July 26, 2016), Legacy Emanuel 
Medical Centre. Supervisor: Dr. Eric Dierks.  
 
2015 Principles of Operative Treatment of Craniomaxillofacial Trauma 
and Reconstruction  
(Continuing Medical Education Activity, AO North America) 
 
2013 North American SORG (Strasbourg Ostheosynthesis Research 
Group) Modular Training Series 2013: Module 2 
   Congenital and Developmental Deformities 
 
 2 
2012 Canadian Dental Society of Anesthesiology  
Annual Scientific Meeting    
“Anesthetic Approaches and When Things Go Bad” 
  
2010   Nobel Biocare Hands On Training 
  
Also trained in: ACLS, ATLS, Principles of Surgery 
 
 
HONOURS AND AWARDS: 
 
2015 Helen Mildred Blythe Allison Undergraduate Award in 
Medicine 
   (Academic Achievement, Medicine) 
 
2014 Best Basic/Clinical Science Collaborative Poster Presentation 
Award 
   (2014 Department of Pathology Annual Research Day) 
 
2012   Dr. A.E. Swanson Award  
(First Year Canadian Oral and Maxillofacial Surgery Resident 
Award)  
 
2010   Dental Association of Prince Edward Island Prize  
   (Greatest Proficiency and Interest in Hospital Dentistry) 
  
Quintessence Award for Research Achievement 
(Exceptional interest and research abilities over four years of 
dental study) 
 
2009   Dr. I.K. Lubetsky Scholarship 
(Greatest Proficiency in the Practice of Clinical Oral Maxillofacial 
Surgery) 
 
Pierre Fauchard Academy Annual Scholarship Award 
(Outstanding Scholarship and Clinical Research at the Dental 
Undergraduate Level) 
  
 
Certificate of Recognition 
   CDA/DENTSPLY, Student Clinician Research Program  
 
United Dental Learning Centre Table Clinic Award 
   (Best Table Clinic Presentation) 
  
Patterson Dental Table Clinic Prize  
   (First place Dentistry Table Clinics) 
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Dr. Bruce N. Fergusson Prize (Best Table Clinic Presentation) 
   Halifax County Dental Society 
 
CDA/Dentistry Student Clinician Award (Best Table Clinic 
Presentation) 
   Canadian Dental Association 
 
Student Table Clinic 1st Place Prize Recipient 
Faculty of Dentistry, Dalhousie University 
 
2007   Charles Bell Memorial Prize 
   (Second Highest Average, First Year Dentistry) 
   Dalhousie University 
 
2006   James P. M. McGuigan Scholarship 
   (Academic Achievement, Dentistry)  
   Dalhousie University 
 
 
PUBLICATIONS: 
 
2016 J. Cox, S. Lownie, J. Armstrong. “Needle Fracture During Inferior 
Alveolar Nerve Block: A Case Report of Management Adjacent 
the Carotid Sheath”. Oral Health. June 2016. 
 
2014 J. Cox, M. Darling, Z. Khan, J. Armstrong. “Expression of human 
tissue kallikriens (KLKs) in Polymorphous Low Grade 
Adenocarcinoma (PLGA)”. Journal of Oral and Maxillofacial Surgery. 
2014; 72: e173 
 
2011 R. Bohay, J. Cox, H.J. Lapointe. “Clinical Decision Making: Cone 
Beam Computed Tomography for the Extraction of Impacted Third 
Mandibular Teeth”. Ontario Dentist. 2011; 88, 7: 27-33. 
 
2009 A. Morrison, J Cox. “Incidence of Osteonecrosis of the Jaw (ONJ) 
in Patients Receiving Intravenous Bisphosphonate Therapy: Data 
From the First 50 Patients”. Journal of Oral and Maxillofacial 
Surgery. 2009; 67, 9: supplement pages 37-39. 
MEMBERSHIPS: 
 
2014-present  Ontario Medical Association 
   Canadian Medical Association 
   International Association for Dental Research 
 
2012-present  Canadian Association of Oral and Maxillofacial Surgeons 
   American Association of Oral and Maxillofacial Surgeons 
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2010-present  Ontario Dental Association  
Royal College of Dental Surgeons of Ontario 
 
2003-present  Golden Key International Honour Society 
 
2009-2010 The International Association of Student Clinicians – American 
Dental Association 
 
    
LEADERSHIP ROLES: 
 
2009-2010 Admissions Interviewer, Faculty of Dentistry, Dalhousie 
University 
 
DDS Student Representative, Dalhousie Student Table Clinics 
Committee 
 
2008-2010  Executive President, Dalhousie Dentistry Class of 2010  
 
2007-2008  Executive Secretary, Dalhousie Dentistry Class of 2010  
Chair, Dalhousie Dentistry Class of 2010 Fundraising: 2007-2008 
 
2005-2006 Secretary & Executive Member, Dalhousie University Society of 
Immunology and Microbiology Students 
  
 
RESEARCH EXPERIENCE:  
 
2012- 2017 “Expression of human tissue kallikriens (KLKs) in Polymorphous Low 
Grade Adenocarcinoma (PLGA)”  
   Candidate for MSc, Pathology 
 Supervisors: Drs Mark Darling, Zia Khan, and JE Armstrong 
University of Western Ontario 
Department of Pathology, Schulich School of Medicine and Dentistry 
 
2007- 2010 “Incidence of Osteonecrosis of the Jaw in Patients 
Receiving/Having Received Intravenous Bisphosphonate Therapy” 
(Prospective Trial at the Nova Scotia Cancer Centre to determine 
the risk of developing ONJ while on intravenous bisphosphonate 
therapy). Student Research Investigator under Dr. Archie Morrison 
  Department of Oral & Maxillofacial Surgery 
Victoria General Hospital, QEII Health Sciences Centre 
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2008-2009 “Incidence of Osteonecrosis of the Jaw in Patients 
Receiving/Having Received Intravenous Bisphosphonate Therapy” 
Research Investigator/Oral & Maxillofacial Surgery Elective 
Student 
Faculty of Dentistry, Dalhousie University 
 
 
PRESENTATIONS: 
 
2017 “Primary Intraosseous Squamous Cell Carcinoma (PIOSCC): A 
Rarely Reported Entity in Paediatrics” (Poster). Presented at the 
ACOMS/CAOMS Joint Annual Conference and Exhibition. 
 
“Human Tissue Kallikreins (KLKs) in Polymorphous Low Grade 
Adenocarcinoma (PLGA)” (Poster). Presented at Department of 
Pathology Annual Research Day. 
 
 
2016 “Expression of human tissue kallikriens (KLKs) in Polymorphous 
Low Grade Adenocarcinoma (PLGA)” (Oral Presentation). 
Presented at the Head and Neck Retreat, London Health Sciences 
Centre. 
 
  “Expression of human tissue kallikriens (KLKs) in Polymorphous 
Low Grade Adenocarcinoma (PLGA)” (Oral Presentation). 
Presented at the CAOMS Annual Conference, Scientific Sessions. 
 
2015 “Expression of human tissue kallikriens (KLKs) in Polymorphous 
Low Grade Adenocarcinoma (PLGA)” (Poster). Presented at the 
93rd General Session & Exhibition of the International Association for 
Dental Research.  
 
“Expression of human tissue kallikriens (KLKs) in Polymorphous Low 
Grade Adenocarcinoma (PLGA)” (Poster). Presented at Department of 
Pathology Annual Research Day. 
 
 
2014 “Expression of human tissue kallikriens (KLKs) in Polymorphous 
Low Grade Adenocarcinoma (PLGA)” (Poster) . Presented at the 
AAOMS 96th Annual Meeting, Scientific Sessions and Exhibition. 
  
“Expression of human tissue kallikriens (KLKs) in Polymorphous Low 
Grade Adenocarcinoma (PLGA)” (Poster). Presented at Department of 
Pathology Annual Research Day. 
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2009 “Incidence of Osteonecrosis of the Jaw (ONJ) in Patients 
Receiving Intravenous Bisphosphonate Therapy: data from the first 
50 patients” (Oral Presentation). Presented at the 
AAOMS/CAOMS 91st Annual Meeting, Scientific Sessions and 
Exhibition.  
 
“Incidence of Osteonecrosis of the Jaw in Patients Receiving/Having 
Received Intravenous Bisphosphonate Therapy” (Poster). Presented at 
Canadian Dental Association Annual Convention and Pacific Dental 
Conference.  
 
“Incidence of Osteonecrosis of the Jaw in Patients Receiving/Having 
Received Intravenous Bisphosphonate Therapy” (Oral Presentation). 
Presented at Student Table Clinics, Faculty of Dentistry, Dalhousie 
University 
 
“Incidence of Osteonecrosis of the Jaw in Patients 
Receiving/Having Received Intravenous Bisphosphonate Therapy” 
(Poster) Presented at Undergraduate Health Sciences Student 
Research Day, Faculty of Medicine, Health Professions and 
Dentistry 
 
2008 “Incidence of Osteonecrosis of the Jaw in Patients 
Receiving/Having Received Intravenous Bisphosphonate Therapy” 
(Poster) Presented at Undergraduate Health Sciences Student 
Research Day, Faculty of Medicine, Health Professions and 
Dentistry 
 
 
  
EMPLOYMENT HISTORY: 
  
2011-2012  General Dentist 
Department of Dentistry, London Health Sciences Centre, London, 
Ontario  
 
 
VOLUNTEER AND COMMUNITY: 
 
2009-2016  Run for the Cure Participant  
 
2015   Do It For Dads Walk Run Participant  
Prostate Cancer Canada  
 
2014   Mental Health 10K Run Participant 
 
2002-2010  Dalhousie University, Faculty of Dentistry 
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Operation Outreach (Dental clinic for local refugees) 
 
One-on-One Volunteer with Veterans  
 
Volunteer Math Tutor 
  
East Coast Music Awards Volunteer  
 
“Hockey for Everyone Volunteer” 
 
